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1. Summary 
1.1. Summary (English) 
The Notch signaling pathway is crucial for mammalian heart development. It controls cell-fate 
decisions, coordinates patterning processes and regulates proliferation and differentiation. Critical 
Notch effectors are Hey bHLH transcription factors (TF) that are expressed in atrial (Hey1) and 
ventricular (Hey2) cardiomyocytes (CM) and in the developing endocardium (Hey1/2/L). The 
importance of Hey proteins for cardiac development is demonstrated by knockout (KO) mice, which 
suffer from lethal cardiac defects, such as ventricular septum defects (VSD), valve defects and 
cardiomyopathy. Despite this clear functional relevance, little is known about Hey downstream targets 
in the heart and the molecular mechanism by which they are regulated.  
Here, I use a cell culture system with inducible Hey1, Hey2 or HeyL expression to study Hey target gene 
regulation in HEK293 cells, in murine embryonic stem cells (ESC) and in ESC derived CM. In HEK293 
cells, I could show that genome wide binding sites largely overlap between all three Hey proteins, but 
HeyL has many additional binding sites that are not bound by Hey1 or Hey2. Shared binding sites are 
located close to transcription start sites (TSS) where Hey proteins preferentially bind to canonical 
E-boxes, although more loosely defined modes of binding exist. Additional sites only bound by HeyL 
are more scattered across the genome. The ability of HeyL to bind these sites depends on the C-
terminal part of the protein. Although there are genes which are differently regulated by HeyL, it is 
unclear whether this regulation results from binding of additional sites by HeyL. 
Additionally, Hey target gene regulation was studied in ESC and differentiated CM, which are more 
relevant for the observed cardiac phenotypes. ESC derived CM contract in culture and are positive for 
typical cardiac markers by qRT-PCR and staining. According to these markers differentiation is 
unaffected by prolonged Hey1 or Hey2 overexpression. Regulated genes are largely redundant 
between Hey1 and Hey2. These are mainly other TF involved in e.g. developmental processes, 
apoptosis, cell migration and cell cycle. Many target genes are cell type specifically regulated causing 
a shift in Hey repression of genes involved in cell migration in ESC to repression of genes involved in 
cell cycle in CM. 
The number of Hey binding sites is reduced in CM and HEK293 cells compared to ESC, most likely due 
to more regions of dense chromatin in differentiated cells. Binding sites are enriched at the proximal 
promoters of down-regulated genes, compared to up-or non-regulated genes. This indicates that up-
regulation primarily results from indirect effects, while down-regulation is the direct results of Hey 
binding to target promoters. The extent of repression generally correlates with the amount of Hey 
- 4 - 
 
binding and subsequent recruitment of histone deacetylases (Hdac) to target promoters resulting in 
histone H3 deacetylation.  
However, in CM the repressive effect of Hey binding on a subset of genes can be annulled, likely due 
to binding of cardiac specific activators like Srf, Nkx2-5 and Gata4. These factors seem not to interfere 
with Hey binding in CM, but they recruit histone acetylases such as p300 that may counteract Hey 
mediated histone H3 deacetylation. Such a scenario explains differential regulation of Hey target genes 
between ESC and CM resulting in gene and cell-type specific regulation. 
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1.2. Zusammenfassung (Deutsch) 
Der Notch Signalweg ist essenziell für die Herzentwicklung in Säugetieren. Er kontrolliert Zell-
differenzierung, koordiniert Musterbildungsprozesse und reguliert Proliferation und Differenzierung. 
Kritische Notch Effektoren sind Hey bHLH Transkriptionsfaktoren, welche im Herzen in atrialen (Hey1) 
und ventrikulären (Hey2) Kardiomyozyten und dem sich entwickelnden Endokardium (Hey1/2/L) 
exprimiert werden. Die Bedeutung von Hey Proteinen während der Herzentwicklung wird an Hand von 
verschiedenen KO Mäusen ersichtlich, welche letale Herzdefekte, wie ventrikuläre Septumdefekte, 
Herzklappendefekte und Kardiomyopathien, entwickeln. Trotz dieser klaren funktionalen Relevanz ist 
wenig über Hey Zielgene im Herzen und den molekularen Mechanismus bekannt, über den diese 
reguliert werden. 
Hier wurde ein Zellkultursystem mit induzierbarer Expression von Hey1, Hey2 oder HeyL verwendet, 
um Hey Zielgene in HEK293, murinen embryonalen Stammzellen und in differenzierten 
Kardiomyozyten zu studieren. In HEK293 Zellen konnte ich zeigen, dass die Bindestellen im Genom 
weitestgehend zwischen allen drei Hey Proteinen überlappen, HeyL jedoch viele zusätzliche 
Bindestellen aufweist, welche weder von Hey1 noch Hey2 gebunden werden. Gemeinsame 
Bindestellen befinden sich nahe Transkriptionsstartstellen, präferentiell an kanonische E-boxen. Die 
nur von HeyL gebunden Bindestellen sind mehr über das Genom verteilt. Dabei ist die Fähigkeit von 
HeyL diese Stellen zu binden vom C-terminalen Teil abhängig. Obwohl es Gene gibt, die unterschiedlich 
von HeyL reguliert werden, ist es auf Grund der sehr viel größeren Anzahl an HeyL Bindestellen unklar, 
ob diese Regulation das Resultat von zusätzlicher HeyL Bindung ist. 
Zusätzlich wurde die Regulation von Hey Zielgenen in embryonalen Stammzellen und differenzierten 
Kardiomyozyten untersucht, da diese Zellen für die beobachteten kardialen Phänotypen relevanter 
sind. Differenzierte Kardiomyozyten kontrahieren in Kultur und sind positiv für typische kardiale 
Marker an Hand von qRT-PCR und Färbungen. Nach diesen Markern ist die Differenzierung durch 
kontinuierliche Überexpression von Hey1 oder Hey2 unverändert. Die Hey1 und Hey2 regulierten Gene 
sind weitestgehend redundant. Viele Zielgene sind andere Transkriptionsfaktoren, die zum Beispiel an 
Entwicklungsprozessen, Apoptose, Zellmigration und dem Zellzyklus beteiligt sind. Diese werden oft 
Zelltyp spezifisch reguliert, was zur Folge hat, dass in embryonalen Stammzellen auch an der 
Zellmigration beteiligte Gene reprimiert werden, während es in Kardiomyozyten vor allem Gene sind, 
die den Zellzyklus betreffen. 
Die Zahl der Hey Bindestellen ist in Kardiomyozyten und HEK293 Zellen verglichen mit embryonalen 
Stammzellen reduziert, höchstwahrscheinlich da differenzierte Zellen weniger offenes Chromatin 
besitzen. Die Bindestellen sind in reprimierten Genen verglichen mit induzierten oder nicht regulierten 
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Genen angereichert. Dies deutet an, dass eine Induktion meist durch indirekte Effekte zu Stande 
kommt, während eine Repression das direkte Ergebnis der Hey Bindung an Zielpromotoren ist. Die 
Stärke der Repression korreliert dabei generell mit der Menge an Promoter gebundenem Hey Protein, 
welches Histon-Deacetylasen rekrutiert und zu einer Reduktion der Histon H3 Acetylierung führt. 
In Kardiomoyzyten wird der repressive Effekt von Hey für bestimmte Gene unterbunden, 
wahrscheinlich durch Bindung herzspezifischer Aktivatoren, wie Srf, Nkx2-5 und Gata4. Diese Faktoren 
scheinen nicht die Bindung von Hey zu beeinflussen, aber sie rekrutieren Acetylasen wie p300, welche 
Hey vermittelter Histon H3 Deacetylierung entgegenwirken. Dieses Model erklärt die unterschiedliche 
Regulation von Hey Zielgenen zwischen embryonalen Stammzellen und Kardiomyozyten. 
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2. Introduction 
Congenital heart defects affect 1 in 100 newborn children, which represent the main share among all 
defects seen in human live births (Hoffman and Kaplan, 2002). For several of these heart defects 
mutations of Notch signaling elements have been shown to be the underlying cause. Notch signaling 
regulates cell-fate specification, differentiation and patterning processes. It acts locally, specifying 
individual fates to single cells or a group of cells within a field of similar cells. It is crucial for the 
development of complex organs, such as the heart, which require the coordinated development of 
numerous individual elements. Several functional studies in mice have demonstrated the importance 
of Notch signaling for cardiovascular development (Xue et al., 1999, Krebs et al., 2000, McCright et al., 
2001, Krebs et al., 2003, Duarte et al., 2004). 
2.1. Hey bHLH transcription factors 
Hairy/enhancer-of-split related with YRPW motif (Hey) proteins are integral members of the Notch 
signaling pathway. There are three mammalian Hey proteins Hey1, Hey2 and HeyL (also known as 
Hrt1/2/3, Hesr1/2/3, Herp2/1/3 or Chf2/1/3) (Kokubo et al., 1999, Leimeister et al., 1999, Sartorelli et 
al., 1999, Chin et al., 2000, Nakagawa et al., 2000, Iso et al., 2001a). They are conserved throughout 
vertebrate development (Winkler et al., 2003) and there is also a single Hey Drosophila homolog 
(Kokubo et al., 1999, Leimeister et al., 1999). In mammals Hey proteins are expressed in various tissues 
during embryonic development including heart and blood vessels and Hey KO mice show various 
defects in these tissues. 
Hey proteins are bHLH factors with a conserved domain structure and they are closely related to the 
Hes family of proteins and the Drosophila hairy and Enhancer of split genes. Common features are a 
basic, a helix-loop-helix (HLH), and an Orange domain that are similar to those of Hes proteins and two 
conserved C-terminal motifs (figure 1).  
 
Figure 1: Domain structure of Hey and Hes proteins 
b = basic; HLH = helix-loop-helix; aa = amino acid; 
The basic domain has a high content of basic amino acids and directly contacts DNA, where it 
preferentially binds E-box sequences in vitro (CACGTG, CACGCG) (Iso et al., 2001b). This is similar to 
b HLH OrangeHey1
Hes
Hey2
HeyL
YRPW…GTEIGAF
YRPW…GTEVGAF
YHSW…GTEIGAF
..G..
..G..
..G..
..P.. WRPW
157-287 aa
299 aa
339 aa
326 aa
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Hes proteins, despite the exchange of a conserved and functionally relevant proline residue within the 
basic domain of Hes proteins to glycine in Hey proteins, which might affect DNA binding (Iso et al., 
2001b, Popovic et al., 2014). The HLH domain serves as a platform for homo- and heterodimerization 
with Hey and Hes proteins as well as for other protein interactions (Iso et al., 2002, Leimeister et al., 
2000a). These dimers form a scissor like structure (Murre et al., 1989, Shimizu et al., 1997), which binds 
to the two strands of DNA such that both basic domains are in direct contact with the DNA. Two further 
α-helices form the Orange domain, which functions as an additional interface for protein interactions. 
Characteristically for Hey proteins are the two conserved C-terminal YRPW (YXXW for HeyL) and 
GTE(I/V)GAF peptides. Contrary to the C-terminal WRPW peptide of Hes proteins, YRPW cannot bind 
TLE corepressors (Paroush et al., 1994, Fisher et al., 1996, Iso et al., 2001b). The function of both C-
terminal Hey motifs is currently unknown. 
2.2. Induction by Notch signaling and crosstalk with other pathways 
Hey and Hes genes are the most prominent targets of canonical Notch signaling in vertebrates and 
they convey a significant part of the Notch signal. They are activated upon juxtacrine binding of Jagged 
or Delta-like ligands (Jag1, Jag2, Dll1, Dll3 and Dll4) to the extracellular domain of Notch receptors 
(Notch1-4) (figure 2). This interaction leads to two consecutive proteolytic cleavages releasing the 
Notch intracellular domain (NICD), which translocates into the nucleus and interacts with the DNA 
binding protein Rbp-Jκ. It displaces corepressors (e.g. N-CoR, Sharp, CtBP) and allows recruitment of 
coactivators (e.g. Mastermind/MAML, p300/CBP) converting the Rbp-Jκ complex from a repressor to 
an activator. 
 
Figure 2: Hey proteins are activated by canonical Notch signalling 
Hey proteins are induced by NICD-Rbp-Jκ activator complex. Bmp/Tgfβ can further induce Hey expression via 
Smad proteins and even activate Hey independent of Notch. 
Hey genes are differentially expressed in several Notch pathway mutants: While Notch1 deletion leads 
to a loss of HeyL expression in somites or the endocardium, overexpression of constitutively active 
Notch1 (N1ICD) in the mesodermal lineage leads to induction of Hey1 (Leimeister et al., 2000b, Firulli 
cleavage
Dll, Jag Notch
NICD
Rbp-Jκ
Bmp/Tgfβ
Smad
P
Rbp-Jκ HeyHey
P
P
Hey dimer
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et al., 2000, Watanabe et al., 2006). However, similar deletion and overexpression experiments with 
Notch2 in the heart or Notch3 in vascular smooth muscle cells did not identify obvious alterations in 
Hey gene expression suggesting a Notch2/3 independent expression in other instances (King et al., 
2006, Kokubo et al., 2007). Reporter gene assays and mutation analysis of Hey promoters clearly 
supported the direct mode of activation via Rbp-Jκ (Maier and Gessler, 2000, Iso et al., 2001a, Iso et 
al., 2002). In these experiments there is little evidence for selectivity of certain Notch receptors 
towards an individual Hey gene. 
In addition to activation by Notch, there is crosstalk with other signaling pathways to enhance Hey 
transcription: Jak2-Stat3 and Jak2-Erk1/2 signaling has been implicated in enhancing Notch activity in 
neuroepithelia and colon carcinoma (Kamakura et al., 2004, Neradugomma et al., 2013). Foxc1 and 
Foxc2 directly induce Hey2 in endothelial cells via Foxc binding elements within the Hey2 promoter 
and via interaction with NICD (Hayashi and Kume, 2008). In zebrafish the Hey2 ortholog gridlock is 
induced by Sox7 and Sox18 during arteriovenous differentiation (Pendeville et al., 2008).  
Tgfβ/Bmp and Notch signaling synergistically control osteoblast and myogenic differentiation 
(Dahlqvist et al., 2003, de Jong et al., 2004), sprouting angiogenesis (Itoh et al., 2004, Moya et al., 
2012), and induce epithelial mesenchymal transition (EMT) (Zavadil et al., 2004). Hey activation by 
Tgfβ/Bmp seems to occur by two different mechanisms (figure 2): On the one hand induction can be 
independent of Notch, driven by direct binding of Smad proteins to the promoter (Zavadil et al., 2004, 
Sharff et al., 2009). On the other hand activation seems to depend on interaction of NICD with Smad1, 
3 and 5, although one study was only able to confirm interaction with Smad3 (Blokzijl et al., 2003, 
Dahlqvist et al., 2003, Itoh et al., 2004, Zavadil et al., 2004).  
CoupTF-II (also known as Nr2f2) is another important regulator of Hey expression in endothelia cells 
as well as in CM. CoupTF-II homodimers directly repress Hey1 and Hey2 in venous endothelia cells (Diez 
et al., 2007, Aranguren et al., 2013b, Korten et al., 2013). However, in lymphatic endothelia cells 
CoupTF-II forms heterodimers with Prox1, which lack this repressive capacity resulting in expression of 
Hey1 and Hey2 (Yoo et al., 2012, Korten et al., 2013). In CM CoupTF-II is also an important Hey 
regulator, it represses Hey2 in atrial CM, but induces Hey1 (Wu et al., 2013). The strong arterial 
expression of Hey proteins suggests that they are part of the hypoxia response. Hypoxia sensing Hif1 
has been shown to induce Hey expression directly (Diez et al., 2007) and via induction of Vegf, Dll4 and 
Jag2 (Patel et al., 2005, Williams et al., 2006, Pietras et al., 2011). 
In conclusion, while Hey proteins are classical downstream acting factors of canonical Notch signaling, 
multiple other signaling pathways control their expression, leading to a cell type specific expression in 
various tissues.  
- 10 - 
 
2.3. Interaction partners 
Hey proteins form homo- and heterodimers via the HLH domain with other Hey and Hes proteins 
(Leimeister et al., 2000a, Iso et al., 2001b, Ross et al., 2006, Fischer et al., 2007). Via the HLH domain 
Hey proteins can also interact with numerous other TF (Fischer and Gessler, 2007). 
Hey1 has been shown to directly interact with N-CoR and Sin3a in vitro (Iso et al., 2001b, Gould et al., 
2009). Both proteins are part of the Sin3 corepressor complex, which recruits histone deacetylases 
(Hdac). Another study found also a direct interaction between Hey2 and Sirt1, which is another histone 
deacetylase, via the bHLH domain (Takata and Ishikawa, 2003). Further evidence comes from studies, 
which show that TSA treatment partially blocks Hey repression as it inhibits Hdacs but does not affect 
Sirt1 (Nakagawa et al., 2000, Takata and Ishikawa, 2003). These results indicate that Hey proteins might 
repress direct target genes via recruitment of histone deacetylases to target promoters.  
 
Figure 3: Hey interaction partner 
Hey and Hes proteins form homo- and heterodimers, they interact with other TF such as e.g. androgen receptor 
(AR), Gata4/6, MyoD or Srf and recruit histone deacetylases (Hdac1/2, Sirt1). 
All three Hey proteins were shown to interact with the androgen receptor and its coactivator Src1 and 
to repress transcription from androgen dependent promoters (e.g. Dat1 promoter) (Kanno and Ishiura, 
2012), possible via recruitment of trichostatin insensitive deacetylases like Sirt1 (Belandia et al., 2005, 
Lavery et al., 2011). Hey proteins also directly interact with Gata TF, this direct interaction prevents 
transcriptional activation of e.g. Anf promoter by Gata4/6 (Kathiriya et al., 2004, Fischer et al., 2005) 
and Myh11 promoter by Gata6 (Shirvani et al., 2006). Hey1 also interacts with MyoD, thereby 
preventing MyoD target gene activation and inhibiting normal muscle cell differentiation (Sun et al., 
2001). Another Hey interacting transcription factor is Srf: Hey1 binding interferes with Srf-CArG box 
binding, preventing Srf dependent target gene activation (Doi et al., 2005). 
The above described interactions indicate that Hey proteins might affect gene expression not only 
directly by E-box binding but also indirectly by affecting other TF. In both cases regulation might be 
mediated by recruitment of histone deacetylases. These not only act on histones but also on other 
proteins including MyoD, Gata factors, and the androgen receptor, which require acetylation to reach 
their full activating potential (Mal et al., 2001, Ozawa et al., 2001, Fu et al., 2003, Hayakawa et al., 
2004). 
Hey/Hes 
homo/ heterodimers
Interaction with other TF
(AR, Gata4/5, MyoD or Srf)
Interaction with cofactors
Hdac1/2
NcoR
Sin3
Sirt1
SrfGata
4/6
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2.4. Known target genes 
Early data for Hey regulated genes comes from individual target gene approaches. In the cardiovascular 
system, Hey proteins were shown to directly repress e.g. Gata4/6 and Tbx2 (Fischer et al., 2005, 
Kokubo et al., 2007). During smooth muscle cell differentiation Hey1 and Hey2 were shown to repress 
Smooth muscle α-actin (Tang et al., 2008) and several papers describe Hey repression of Nfatc1 and 
Runx2, thereby inhibiting osteoblast differentiation (Jing et al., 2010, Salie et al., 2010, Tu et al., 2012). 
There have been few genome and transcriptome wide screens to identify Hey target genes: A first 
screen was performed in endothelia cells overexpressing Hey2 to see whether an arterial fate could be 
induced (Chi et al., 2003). Hey2 was found to activate expression of arterial specific genes, including 
Adha1, Eva1, and keratin7, while repressing myosin I, suggesting that Hey2 turns on features of artery 
specific gene expression program. However, a more recent publication found that Hey2 
overexpression is not sufficient to induce arterial cell fate (Aranguren et al., 2013a). 
For another screen Hey2 KO and wild-type mouse aortic smooth muscle cells were treated with platelet 
derived growth factor (PDGF), which induced proliferation and migration in wild-type but not in KO 
cells. Target genes were identified at different time points after PDGF induction and yielded a 
surprisingly large number of 9 827 transcripts with altered expression (Shirvani et al., 2007). Many 
identified genes have roles in vascular smooth muscle function, e. g. hyaluronan synthase 1, which was 
only up-regulated after PDGF treatment in Hey2 KO cells, indicating repression by endogenous Hey2 
(Shirvani et al., 2007). However, the large number of identified genes makes it difficult to identify 
meaningful groups.  
Another screen used primary neonatal mouse CM from wild type and transgenic mice overexpressing 
Hey2, which are protected from phenylephrine induced hypertrophy. They found genes involved in 
water transport, adenylate cyclase activity, embryonic eye morphogenesis, gut development and fluid 
transport to be repressed by Hey2 (Yu et al., 2010). 
2.5. Hey factors in development 
The wide-ranging expression of Hey genes, controlled by Notch signaling, crosstalk with other signaling 
pathways, and a wide variety of downstream targets result in multiple functions of Hey proteins in 
development and tissues homeostasis.  
The importance of Hey proteins for cardiovascular development was demonstrated by various Hey KO 
mice. While there are no developmental defects in Hey1 and HeyL KO mice (Fischer et al., 2004b, 
Fischer et al., 2007), the Hey2 KO is lethal within the first ten days after birth due to VSD and cardiac 
valve defects (Gessler et al., 2002, Donovan et al., 2002, Sakata et al., 2002, Kokubo et al., 2004). 
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Combined loss of Hey1 and HeyL leads to similar deficiencies with membranous VSD and dysplastic 
atrioventricular and pulmonary valves (Fischer et al., 2007). The combined loss of Hey1 and Hey2 is 
embryonic lethal at around E9.5/E10.5 due to global lack of vascular remodeling and hemorrhaging 
and even more severe cardiac defects (Fischer et al., 2004b, Kokubo et al., 2005). 
2.5.1. Hey factors in cardiac development 
The heart is the first functional organ to develop during vertebrate embryogenesis and development 
starts in mice around embryonic day E7.5. A subset of mesodermal cells migrates antero-laterally to 
form the cardiac crescent and fuse into a single heart tube. Cardiogenic progenitors already express 
the earliest cardiac marker Nkx2-5, which induces further cardiac genes e.g. Bmp2 and Tbx2/3 that 
drive differentiation. Mesodermal cells differentiate into the endocardium lining heart chambers and 
valves and the myocardium forming the musculature of ventricles and atria. At E9.5, a third cardiac 
tissue, the epicardium develops from cells arising from mesodermal cells posterior to the inflow region, 
which migrate and cover the entire myocardial surface. At the same time the heart tube undergoes 
characteristic looping and the typical heart structure is established. Atrial and ventricular parts further 
expand by proliferation and recruitment of mesenchymal cells. 
Hey1 is expressed in myocardial cells of the atrium, the developing inflow and outflow tract, whereas 
Hey2 is expressed in myocardial cells of the ventricle, the outflow tract and the cushion mesenchyme 
of the outflow tract (figure 4) (Leimeister et al., 1999, Nakagawa et al., 1999, Donovan et al., 2002). 
Myocardial expression of Hey1 and Hey2 plays a role in establishing the atrioventricular canal (AVC) 
boundary by repressing Tbx2 and Bmp2 (Kokubo et al., 2007, Luna-Zurita et al., 2010). 
At the same time the atrial and ventricular septa are formed, which consist of a muscular part and 
membranous parts that originate from endocardial cells of the AVC. All three Hey proteins are 
expressed in these endocardial cells (figure 4) (Fischer et al., 2007). These cells undergo EMT and 
mesenchymal cells subsequently proliferate and differentiate to develop the membranous septum as 
well as valvular leaflets. This process is impaired in Hey1/L and Hey2 KO mice as demonstrated by 
atrioventricular explants that exhibited strongly reduced EMT (Fischer et al., 2007). In line with this, 
Notch1 induced myocardial expression of Hey1 in the AVC leads to Bmp2 repression, which 
subsequently also impairs endocardial EMT (Luna-Zurita et al., 2010). Due to these EMT defects, 
Hey1/L and Hey2 KO mice at later stages develop a membranous VSD with overriding aorta and also 
atresia or abnormalities of the tricuspid valve and atrial septal defects (ASD) were observed (Donovan 
et al., 2002, Kokubo et al., 2004, Fischer et al., 2004a). 
- 13 - 
 
 
Figure 4: Hey expression in the developing heart and defects in KO mice 
(A) At embryonic day E9.5 Hey1 is expressed in CM of the developing atrium (at), while Hey2 is expressed in CM 
of the future right and left ventricle (rv, lv). All three Hey proteins are expressed in the endocardium. Hey2 and 
Hey1/L KO mice exhibit EMT defects in the endocardium of the AVC. Oft = outflow tract 
(B) At embryonic day E14.5 Hey1 and Hey2 are expressed in CM of the left and right atrium (la, ra) and ventricles 
(lv, rv), respectively. Hey2 KO mice have ventricular septum defects (VSD), valve defects and atrial septum defects 
(ASD). These are the result of the earlier EMT defect, as these structures develop from mesenchymal cells, which 
have undergone EMT. 
The ventricles further mature through trabeculation and compaction of CM. Ventricular myocardial 
Hey2 expression is important for suppressing atrial gene expression in the left ventricular myocardium, 
thereby allowing proper maturation and compaction (Koibuchi and Chin, 2007, Xin et al., 2007). In the 
atria, Hey2 expression is suppressed by the transcription factor CoupTF-II (Wu et al., 2013).  
Consistently, CM specific CoupTF-II KO mice developed ventricularized atria. Hey2 KO mice show an 
increase in heart size with enlarged ventricles and an abnormal pear-like shape (Gessler et al., 2002, 
Donovan et al., 2002, Sakata et al., 2002, Kokubo et al., 2004). Myocardial Hey2 overexpression in Hey2 
KO mice could rescue myocardial and also septation defects, but not aortic and valve defects 
suggesting a combinatorial effect of Hey2 in different cell types (Sakata et al., 2006).  
2.5.2. Hey factors in adult cardiac disease 
In a mixed genetic mouse background Hey2 KO mice reach adulthood and develop heart failures with 
cardiac hypertrophy being a possible reason (Sakata et al., 2006). Also heterozygous deletion of Hey2 
enhanced cardiac hypertrophy and progression to heart failure with increased apoptosis and elevated 
Gata4 levels (Liu et al., 2010). Further studies implicated abnormalities in calcium cycling mediated by 
ryanodine receptor binding protein (Fkbp12.6), which was induced in myocardial specific Hey2 KO mice 
after aortic banding (Liu et al., 2012). Hey2 overexpression, on the other hand, is protective against 
phenylephrine-induced hypertrophy, possibly via suppression of hypertrophic genes like Anf, Bnp, and 
Gata4 (Xiang et al., 2006). In a mouse model for pressure overload hypertrophy, Hey2 overexpression 
at
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promoted physiological over pathological hypertrophy (Yu et al., 2009). Here, the authors implicated 
suppression of apoptosis and regulation of multiple transcriptional pathways. 
Recently, a genome-wide association study described genetic polymorphisms in the HEY2 gene as a 
regulator of cardiac electrical function involved in Brugada syndrome (Bezzina et al., 2013). In Hey2 KO 
mice the expression of the Brugada syndrome associated cardiac sodium channel Nav1.5 in the 
compact ventricular layer was higher compared to wild-type hearts and conduction velocity in the right 
ventricular outflow tract was increased. This suggests an additional regulatory role for Hey2 in 
repolarizing currents. 
2.5.3. Hey factors in vascular development 
During embryonic development new blood vessels are formed by two separate processes: (1) During 
vasculogenesis mesodermal progenitor cells differentiate into embryonic blood cells and endothelial 
cells, which aggregate into blood islands and build the primary vascular plexus (Flamme et al., 1997). 
The primary vascular plexus then forms the extra-embryonic yolk sac vasculature and intra-embryonic 
aorta and cardinal vein. (2) The complex vascular network is formed by angiogenesis, when endothelial 
cells become motile and form new capillaries by sprouting from pre-existing vessels (Risau, 1997). 
 
Figure 5: Regulation of Hey expression in endothelial cells 
In arterial endothelial cells Hey is directly induced by hypoxia sensing Hif1 and by VEGF stimulation via the Delta-
Notch pathway. In venous endothelial cells Hey transcription is repressed by CoupTF-II homodimers. In lymphatic 
endothelial cells repression by CoupTF-II is abolished by Prox1, which forms heterodimers with CoupTF-II and 
blocks its repressive capacity towards Hey genes. 
Through extensive remodeling, arterial and venous blood vessels are formed as well as lymphatic 
vessels that arise from developing veins. All three vessel types are morphologically and functionally 
different. Hey proteins are confined to arteries through expression of the Hey antagonist CoupTF-II in 
veins (figure 5) (Nakagawa et al., 1999, Leimeister et al., 2000b). CoupTF-II was found to bind directly 
to the Hey1 and Hey2 promoter and overexpression in human arterial endothelial cells led to down-
regulation of Hey2 and other arterial markers (Aranguren et al., 2013b, Korten et al., 2013). However, 
repression of CoupTF-II by Hey remains controversial. On the one hand hypoxia-induced Hey1 and Hey2 
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expression in embryonic endothelial cells was shown to repress CoupTF-II and to induce an arterial cell 
fate (Diez et al., 2007), on the other hand Hey2 knockdown in human arterial or overexpression in 
venous endothelial cells did not influence CoupTF-II expression (Korten et al., 2013).  
In zebrafish the Hey2 ortholog gridlock is necessary for proliferation of vascular progenitor cells (Zhong 
et al., 2000, Chun et al., 2011). Diminished gridlock expression leads to arterial reduction and 
expansion of the vein region (Zhong et al., 2001). In the mouse neither Hey1 nor Hey2 are essential for 
embryonic vessel development on their own. However, Hey1/Hey2 DKO mice die at embryonic day 
E9.5 due to global lack of vascular remodeling and hemorrhaging (Fischer et al., 2004b, Kokubo et al., 
2005). Arterial endothelial markers like EphB2 and smooth muscle cells markers like smooth muscle 
actin and Sm22 are reduced indicating that Hey1 and Hey2 activity is required for arterial specification. 
However, despite the importance of Hey proteins for arterial differentiation, Hey2 was only able to 
partially restore arterial gene expression in cell culture experiments (Aranguren et al., 2013a). Only in 
combination with seven other TF it was possible to convert human venous endothelial cells robustly 
into arterial endothelial cells. In line with these findings, Hey1 and Hey2 expression in human umbilical 
vein endothelial cells has been shown to suppress the venous endothelial marker EphB4, but was 
unable to induce arterial EphB2. This suggests that Hey proteins repress venous rather than induce 
arterial fate (Iso et al., 2006).  
2.5.4. Hey factors in other developmental processes 
Apart from these cardiovascular functions, Hey proteins are also involved in myogenesis, bone 
formation and neuronal development (figure 6). Hey1/HeyL DKO myoblasts generate fewer quiescent 
satellite cells during development and these gradually decrease with age leading to severe impairment 
of adult muscle homeostasis (Fukada et al., 2011). Several studies provide evidence that all three Hey 
proteins, as well as Hes1, are at least partly responsible for controlling osteoblast differentiation. Mice 
deficient in Hey1 and HeyL, exhibited high bone mass, due to higher numbers of osteoblasts (Tu et al., 
2012). Contrary, transgenic Hey1 overexpression leads to progressive osteopenia in adult mice (Salie 
et al., 2010). Hey1 and Hey2 misexpression by electroporation in the mouse brain at embryonic day 
E13.5 leads to an increase of neural precursor cells, however, at later stages it inhibits neurogenesis 
and promotes generation of astroglia (Sakamoto et al., 2003). 
The main function of Hey proteins during these specification processes seems to be the maintenance 
of tissue specific progenitor cells and preventing exceeding differentiation. 
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Figure 6: Hey proteins control lineage specific differentiation processes 
Hey proteins repress target genes that drive differentiation within certain lineages and thereby affect myogenic, 
osteogenic, and neuronal differentiation. 
2.6. Aim of the Thesis 
The loss of either Hey2 or Hey1/HeyL leads to a severe cardiovascular phenotype and early embryonic 
lethality in vivo. However, only few relevant Hey target genes are known and little is known about their 
regulation. The goal of my thesis was to identify new target genes involved in cardiovascular 
development and the regulatory mechanisms. Therefore, HEK293 cells, murine ESC and in vitro 
differentiated CM with inducible Hey1, Hey2 or HeyL (only in HEK293 cells) expression were used. Gene 
expression was analyzed by microarray or RNAseq and DNA binding sites were identified by ChIPseq. 
Public available data for TF binding sites and histone modifications was used to investigate the 
regulatory mechanisms involved in Hey target gene regulation. 
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3. Materials 
3.1. Equipment 
Table 1: Equipment used 
Berthold Tristar multimode reader Berthold, Germany 
Bioruptor Standard sonifier Diagenode, USA 
Illumina GAIIx Sequencer Illumina, USA 
Leica Fluoreszenz Mikroskop DMI 6000B Leica, Germany 
Mastercycler ep realplex Eppendorf, Germany 
NanoDrop ND-1000 Spektrophotometer  PeqLab, USA 
Nikon Eclipse TS100 with Intenslight C-HGFI Nikon, Japan 
3.2. Disposables and chemicals 
All used disposables, were either purchased from Sarstedt (Germany) or Eppendorf (Germany). 
Chemicals that are not listed separately were either purchases from ROTH (Germany), Sigma-Aldrich 
(Germany) or AppliChem (Germany). All enzymes used for cloning are either derived from Fermentas 
(Lithuania) or NEB (USA). Oligonucleotides listed in supplementary tables 13 – 18 were purchased from 
Sigma-Aldrich (Germany). 
Table 2: Chemicals used 
Beta-mercaptoethanol PAN, Germany 
CHIR99021 Axon, Netherlands 
DMEM Sigma-Aldrich, Germany 
Fetal calf serum (FCS, lot was tested for efficient 
CM differentiation) 
Sigma-Aldrich, Germany 
His-taq polymerase self-made 
Leukaemia inhibitory factor (LIF) self-made 
MEM non-essential amino acids 100X Sigma-Aldrich, Germany 
Metafecten Pro Biotex, Germany 
PD0325901 Axon, Netherlands 
Penicillin/Streptomycin 100X PAA, Germany 
peqGOLD TriFast PeqLab, Germany 
Polyethylenimin (PEI) Eurogentec, Belgium 
Roche Complete Roche, Switzerland 
Sera-Mag magnetic oligos Thermo Scientific, USA 
SybrGreen Ambrex, USA 
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3.3. Buffers 
Table 3: Used buffers 
Standard buffers  
PBS 150 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.8 mM KH2PO4 
TE 10 mM Tris pH 8.0, 1 mM EDTA 
DNA work  
10X DNA loading dye 50 % glycerine, 15 % ficoll, 10 mM EDTA pH 8.0 
10X PCR buffer 200 mM Tris pH 8.8, 100 mM ammonium sulphate, 100 mM KCl, 
20 mM magnesium sulphate, 1 % TritonX-100, 1 % BSA-acetylated 
20X SB 200 mM NaOH pH 8.0 with boric acid 
50X TAE 50 mM EDTA, 2 M Tris pH 8.0 with acetate 
Protein work  
RIPA buffer 50 mM Tris pH 8.0, 1 % Nonidet P40, 0.5 % Sodium deoxycholate, 
0.1 % SDS, 150 mM NaCl, 1X Roche Complete protease inhibitor, 
50 µg/ml PMSF 
2X Protein loading buffer 100 mM Tris pH 6.8, 4 % SDS, 0.25 % Bromophenol blue, 25 % 
glycerine, 200 mM DTT 
Detection buffer 100 mM Tris pH 8.0, 250 mM luminol, 90 mM coumaric acid, 
0.01 % H2O2 
SDS running buffer  25 mM Tris pH 8.3, 192 mM Glycine, 1 % SDS 
Blotting buffer 25 mM Tris pH 8.3, 150 mM Glycine, 10 % Methanol 
Luciferase assay  
Assay buffer 25 mM glycyl-glycine pH 7.8, 15 mM magnesium sulphate, 15 mM 
potassium phosphate, 4 mM EGTA, 1 mM DTT, 1 mM ATP and 1 
µg/µl Luciferin 
Cell lysis buffer 25 mM glycyl-glycine pH 7.8, 15 mM magnesium sulphate, 15 mM 
potassium phosphate, 4 mM EGTA, 1 mM DTT and 2 % TritonX-
100 
EMSA  
Binding buffer 20 mM Tris pH 7.6, 100 mM KCl, 0.5 mM EDTA, 0.1 % Nonidet P-
40, 1 mM MgCl2 , 1 mM DTT, 10 % glycerol 
ChIP buffer  
ChIP dilution buffer 0.01 % SDS, 1.1 % TritonX-100, 1.1 mM EDTA, 20 mM Tris pH 8.0, 
167 mM NaCl, 1X Roche Complete protease inhibitor, 50 µg/ml 
PMSF 
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Elution buffer 50 mM Tris pH 8.0, 10 mM EDTA, 1 % SDS 
High salt wash buffer 500 mM NaCl, 2 mM EDTA, 10 mM Tris-HCl pH 8.0, 1 % 
TritonX-100, 0.1 % SDS, 1X Roche Complete protease inhibitor, 50 
µg/ml PMSF 
LiCl wash buffer 250 mM LiCl, 1 mM EDTA, 10 mM Tris-HCl pH 8.0, 0.5 % 
Nonidet P-40, 0.5 % SDS, 1X Roche Complete protease inhibitor, 
50 µg/ml PMSF 
Low salt wash buffer 150 mM NaCl, 2 mM EDTA, 10 mM Tris-HCl pH 8.0, 1 % 
TritonX-100, 0.1 % SDS, 1X Roche Complete protease inhibitor, 50 
µg/ml PMSF 
Lysis buffer 50 mM Hepes-KOH pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 % 
TritonX-100, 0.1 % Deoxycholate, 0.1 % SDS, 1X Roche Complete 
protease inhibitor, 50 µg/ml PMSF 
Nuclei lysis buffer 50 mM Hepes-KOH pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 % 
TritonX-100, 0.1 % Deoxycholate, 1 % SDS, 1X Roche Complete 
protease inhibitor, 50 µg/ml PMSF 
3.4. Kits 
Table 4: Used kits 
Cycle pure kit Omega Bio-Tek, USA 
Experion DNA 1K analysis kit Bio-Rad, USA 
Experion RNA HighSense analysis kit  Bio-Rad, USA 
Gel extraction kit Omega Bio-Tek, USA 
Gel extraction kit Qiagen, Germany 
NEBnext DNA library prep master mix set for Illumina NEB, USA 
NEBnext mRNA library prep master mix set for Illumina NEB, USA 
NEBnext multiplex oligosfor Illumina (Index Primer Set 1) NEB, USA 
PCR purification kit Qiagen, Germany 
PIERCE LightShift Chemiluminescent EMSA kit PIERCE, USA 
Plasmid midi kit Omega Bio-Tek, USA 
Plasmid mini kit Omega Bio-Tek, USA 
RNeasy kit Qiagen, Germany 
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3.5. Antibodies 
Table 5: Used antibodies 
α-Cardiac Troponin I (TI-1) Mouse  Developmental Studies Hybridoma Bank, USA 
α-Flag-M2 Mouse H9658 Sigma-Aldrich, Germany 
α-H3ac Rabbit 06-599 Upstate, USA 
α-H3k27ac Rabbit 39133 Active Motive, USA 
α-H3k27me3 Mouse Ab6002 Abcam, UK 
α-H3K4me3 Rabbit Ab8580 Abcam, UK 
α-HA Mouse F3165 Sigma-Aldrich, Germany 
α-Hdac2 Mouse Ab51832 Abcam, UK 
α-IgG Rabbit I5006 Sigma-Aldrich, Germany 
α-Mouse-Alexa568 Goat A11031 Molecular Probes, USA 
α-Mouse-POD Goat AP124P Chemicon International, USA 
α-Myosin (MF20) Mouse  Developmental Studies Hybridoma Bank, USA 
α-Tubulin Mouse T6074 Sigma-Aldrich, Germany 
3.6. Plasmids 
To generate Hey inducible cell lines, expression constructs with minitol flanking sites or viral expression 
constructs were used (figure 7). 
 
Figure 7: Doxycycline inducible Hey expression constructs 
FS = Flag-Strep-tag;  
ptol2-FS-mHey1-iE-ins-WHE (12 464 bp)
ptol2-FS-mHeyL-iE-ins-WHE (12 812 bp)
ptol2-FS-mHey2-ins-WHE (11 287 bp)
A) minitol expression constructs
B) Viral expression constructs
p199-FS-mHey1-iEP (9 272 bp)
p199-FS-mHey2-iEP (9 398 bp)
pEF1TA-FS-mHeyL (10 957 bp)
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For constitutive expression of Flag or HA tagged Hey1, Hey2 or HeyL proteins under the control of the 
CMV promoter several pCS2p expression plasmids were used (Rupp et al., 1994): pCS2p-Flag-mHey1, 
pCS2p-Flag-mHey2, pCS2p-Flag-mHeyL, pCS2p-HA-mHey1, pCS2p-HA-mHey2 and pCS2p-HA-mHeyL 
(Fischer et al., 2005).  
Two constructs pCS2p-Flag-mHeyL-1 and pCS2p-Flag-mHey1-L expressing either the C-terminal part of 
Hey1 fused to the N-terminal part of HeyL or vice versa were generated. In both cases the junction 
between both protein parts is directly before or after the conserved region containing bHLH and 
Orange domain, which in both cases was derived from HeyL (see figure 8). 
 
Figure 8: Hey1 and HeyL chimeric proteins 
Both chimeric proteins Hey1-L and HeyL-1 contain the basic (b), helix-loop-helix (HLH) and Orange domains from 
HeyL. The adjacent N- or C-terminal regions are replaced with the matching parts from Hey1. 
Additionally, a previously generated non-binding Hey1 mutant (pCS2p-Flag-mHey1-RK3) with three 
point mutations within the basic domain converting three arginine residues to lysine was used (Heisig 
et al., 2012). The same point mutations were introduced into the chimeric Hey1-L protein by PCR 
mediated mutation (pCS2p-Flag-mHey1-L-RK3). An activating Hey1 variant was generated by fusing 
the vp16 activator domain with the bHLH and Orange domains from Hey1 (pCS2p-vp16-mHey1-bHO). 
For luciferase assay the following constructs containing the firefly luciferase gene under control of a 
promoter of interest were used: pluc-Hey1 (-2839/+87), pGL4.1-JAG1 (-573/0), pLuc-NEUROG3 
(-1700/0), and pGL3-BMPR1A (-519/0). The Hey1 luciferase construct was previously generated by M. 
Maier (Maier and Gessler, 2000). The JAG1 luciferase promoter construct was obtained from H. Kovar 
(Ban et al., 2008), the NEUROG3 construct from M. S. German (Lee et al., 2001), and the BMPR1A 
construct from J. Howe (Calva-Cerqueira et al., 2010). 
3.7. Cell lines 
HEK293T cells containing the SV40 large T-antigen were used for transient transfection. For Hey 
overexpression experiments the previous by lentiviral transfection generated HEK293 cell lines 
HEK293-pWHE134-p199-FS-mHey1-iEP and -mHey2-iEP were used (Heisig et al., 2012). These express 
Hey proteins with Flag-Strep-tag under control of a doxycycline inducible promoter. For HeyL the 
inducible cell line HEK293-pTol2-FS-mHeyL-iEins-WHE generated by tol2-mediated transposition with 
pKate-N/Tol2 was used (Balciunas et al., 2006). These cell lines are called HEK293-Hey1, -Hey2 and -
HeyL further down. Additionally a second doxycycline inducible HeyL cell line HEK293-EF1TA-FS-mHeyL 
was generated by lentiviral transfection. 
HeyL
HeyL-1: N Cb HLH OrangeHey1-L: N Cb HLH Orange
Hey1 HeyL Hey1
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Previously the murine embryonic stem cell line CM7/1 containing a neomycin resistance under the CM 
specific myosin heavy chain promoter (MHCneo) was used to generate ESC with inducible Hey 
expression (Zandstra et al., 2003). Two doxycycline inducible cell lines were generated by transfection 
with Metafecten Pro and tol2-mediated transposition: CM7/1-pTol2-FSmHey1-iE-ins-WHE and CM7/1-
pTol2-FSmHey2-ins-WHE (Heisig, 2011). These are called ES-Hey1 and ES-Hey2 further down. 
3.8. Mouse lines 
Hey1, Hey2 and HeyL KO mouse lines have been described before (Fischer and Gessler, 2007, Fischer 
et al., 2004b). The Act-Hey1 transgenic line expressing Hey1 under the control of the beta-actin 
promoter was obtained from M. Susa (Salie et al., 2010). 
3.9. Data 
Microarray expression and ChIPseq binding data for Hey1 or Hey2 overexpressing HEK293 cells  and 
murine ESC  was previously generated by Julia Heisig (Heisig et al., 2012, Heisig, 2011). 
The HEK293T POLII ChIPseq data with the accession number GSE11892 was obtained from NCBI (Sultan 
et al., 2008). The HEK293 H3K4me3 and CTCF ChIPseq data was obtained from the ENCODE project 
(ENCODE, 2011). The Srf, Nkx2-5 and Gata4 binding data in HL1 cells was derived from He et al. (2011). 
ESC and heart H3K4me3 and H3K27ac ChIPseq data was also derived from the ENCODE project 
(ENCODE, 2011). 
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4. Methods 
4.1. Cloning  
All cloning was done using standard molecular methods. Cloned constructs were always verified by 
Sanger sequencing. 
The non-binding HeyL mutant was generated with overlap extension PCR (Higuchi et al., 1988). 
Therefore, two complimentary primers containing the desired mutations were used in combination 
with a matching forward or reverse primer to amplify two separate PCR products, which overlap at the 
mutation. These PCR products were purified, mixed in stoichiometric ratio 1:1 and amplified in a 15 
cycle PCR reaction without any primers. After that end primers were added and the sample was 
amplified for another 20 cycles. The final product was then size selected using gel electrophoresis and 
cloned in a pCS2p expression vector. 
A mutated version of the JAG1 construct lacking a Hey bound E-box binding motif within the promoter 
region was generated by cutting with MluI, removing the 5’ overhangs with Mung Bean nuclease, and 
religation of the construct, thus removing 4 nucleotides within a Hey bound E-box motif. 
4.2. Cell culture 
HEK293 and HEK293T cells were cultured at 37 °C and 5 % CO2 in DMEM medium containing 10 % FCS 
and penicillin/streptomycin (100 U/ml / 100 µg/ml). 
CM7/1 murine ESC were grown at 37 °C and 5 % CO2 in DMEM supplemented with 15 % FCS, glutamine 
(4 mM), MEM non-essential amino acids (1 %), beta-mercaptoethanol (100 mM),  
penicillin/streptomycin (100 U/ml / 100 µg/ml), leukaemia inhibitory factor (LIF, 1000 U/ml), glycogen 
synthase kinase 3 (GSK3) inhibitor CHIR99021 (3 µM), and the mitogen-activated protein kinase (MEK) 
inhibitor PD0325901 (1 µM) (Ying et al., 2008) on porcine skin gelatine (0.2 %) coated cell culture 
dishes. 
For differentiation in embryoid bodies (EB), 106 cells were seeded in 10 ml DMEM supplemented with 
10 % FCS, glutamine (4 mM), MEM non-essential amino acids (1 %), beta-mercaptoethanol (100 mM), 
and penicillin/streptomycin (100 U/ml / 100 µg/ml). Cells were kept on agitating petri-dishes (50 rpm) 
at 37 °C and 5 % CO2. At day 3, 5, 7 and 9 the medium was changed. Therefore, EB were sedimented 
in 50 ml falcon tubes, old medium was removed, and after addition of new medium the suspension 
was transferred back on the original petri dishes. Starting from day 10 G418 (0.4 mg/ml) was added to 
the differentiation medium to select for CM (myosin heavy chain driven neomycin resistance, 
MHCneo). The medium was changed every day for 5 more days, in order to remove dead cells. At day 
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15 EB were washed twice with PBS and incubated for up to 15 min in 5 ml Trypsin (0.25 % in PBS) until 
they were completely dissociated into single cells. 5*107 cells were than plated on porcine skin gelatine 
(0.2 %) coated 10 cm cell culture dishes. 
4.3. Transfection 
105 cells were seeded on 24-well-dish (5 x 105 cells on a 6-well-dish or 5 x 106 cells on a 10 cm-dish) 
and transfected with 0.5 µg plasmid DNA (3 µg for 6-well-dish or 8 µg for 10cm-dish). For transfection 
two times the DNA amount of either Polyethylenimine (PEI, for HEK293T) or Metafecten Pro (for ESC) 
was used. For PEI transfection DNA and PEI were mixed in 70 µl serum-free DMEM and vortexed. After 
15 min incubation at RT the solution was added to the cells. Transfection with Metafecten Pro was 
done according to manufacturer’s recommendations. The medium was changed after 6 to 8 h. Cells 
were harvested 48 h after transfection. 
4.4. Immunofluorescence 
Cells were grown on cover slips and fixed with methanol/acetone (7:3) at -20 °C for 10 min, washed 
twice with PBS at RT for 5 min and blocked in goat serum (10 %) in a humidified chamber at RT for 
30 min. Cover slips were then incubated in primary antibody (undiluted hybridoma MF20 or TI-1) at 
37 °C for 1 h, washed three times with PBS at RT for 5 min and incubated with secondary antibody 
(α-Mouse-Alexa568 1:500) in PBS with 0.5 % BSA in a humidified chamber at 37 °C for 45 min. After 
that nuclei were stained with Hoechst 33342 in PBS (0.5 µg/ml) at RT for 5 min to label nuclei, washed 
twice with PBS at RT for 5 min and embedded in mowiol. 
4.5. Luciferase Assay 
105 HEK293T cells were plated on 24-well-plates and transfected in triplicates with 250 ng of the 
luciferase reporter construct and 50 ng of the construct containing a potential effector. 48 h after 
transfection cells were washed twice with PBS and incubated for 15 min in 150 µl cell lysis buffer. The 
suspension was then transferred in tubes and spun down for 10 min at 4 °C at Rmax. 50 µl of the 
supernatant were transferred on a black 96-well-microtiter plate. A Berthold Tristar multimode reader 
was used to inject 100 µl assay buffer and measure luminescence for 5 sec. 
4.6. EMSA 
EMSA was performed in binding buffer with 1 ng recombinant MBP-Hey1 protein, 1 mg poly-dAdT, 
5 ng biotin labeled probe and either 0, 25, 75 or 250 ng competing unlabeled probe in a total volume 
of 10 ml. After incubation on ice for 30 min, samples were loaded on a 6 % polyacrylamide gel and later 
- 25 - 
 
blotted onto Amersham Hybond N+ membranes. Detection was done using the PIERCE LightShift 
Chemiluminescent EMSA kit according to the manufacturer’s recommendations. 
4.7. RNA Isolation 
RNA was isolated either from cell culture or mouse heart tissue. For cell culture 500 µl peqGOLD TriFast 
(PEAQLAB, Germany) were added directly to a 10 cm cell culture dish. Tissue was homogenized in 1 ml 
peqGOLD TriFast with an Omni tissue homogenizer (Omni International, USA) for up to 2 min. After 
that RNA was isolated according to manufacturer’s recommendations. The RNA concentration was 
determined by absorbance using a Nanodrop. 
4.8. Quantitative realtime PCR 
2 or 3 µg RNA were reverse transcribed using the Revert Aid First-Strand cDNA synthesis Kit (Thermo 
Scientific, USA) with oligo(dT)-primers according to manufacturer’s recommendations. qRT-PCR 
reactions contained 1/100 of the cDNA reaction or for ChIP samples 1/25 of precipitated DNA (PCR 
reaction shown in table 6). PCR was performed with annealing at 60 °C and SybrGreen quantification 
(PCR program shown in table 7). PCR products were confirmed by melting curve analysis and SB 
agarose gel electrophoresis. The housekeeping gene HPRT was used to normalize expression levels. All 
measurements were done as technical duplicates of biological triplicates for cDNA samples and 
technical duplicates of biological duplicates in case of ChIP samples. 
Table 6: qRT-PCR reaction 
2.5 µl  10X PCR buffer 
1.5 µl Ethylenglycol 
0.25 µl  dNTPs 100 mM 
0.75 µl SybrGreen 1:2000 in H2O 0.5 % DMSO 
0.25 µl His-taq 15 u/µl 
0.75 µl 5’ primer 10 pmol 
0.75 µl 3’ primer 10 pmol 
13.25 µl H2O 
5 µl cDNA / DNA Template 
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Table 7: qRT-PCR program 
95°C 3 min Initial denaturation 
 95°C   15 sec     Denaturation  
 60°C   10 sec                        Annealing 40 cycles 
 72°C   20 sec   Elongation  
55 – 95°C 10 min Melting curve (+4 °C/min) 
16°C  End of program 
4.9. Transcriptome sequencing 
For transcriptome sequencing RNA was isolated using the Qiagen RNeasy Mini Kit according to 
manufacturer’s recommendation. Quality was assessed with an Experion RNA HighSense analysis kit. 
mRNA was isolated from total RNA using Sera-Mag magnetic oligos according to the Illumina 
transcriptome sequencing library preparation protocol. The sequencing library was generated using 
the NEBnext mRNA library prep master mix set for Illumina. In short, mRNA was transcribed into cDNA 
and fragmented into 200 bp fragments. Fragments were end-polished and Illumina sequencing 
adapters were attached. In between these steps samples were purified using the Qiagen PCR 
purification kit. DNA fragments ranging from 200 – 300 bp were excised from an agarose gel using 
Qiagen gel extraction kit and subjected to 12 cycles of PCR amplification. The cDNA library was 
assessed with the Experion DNA 1K kit. After that samples were multiplexed and sequenced on an 
Illumina GAIIx platform. 
33 bp sequences were generated and mapped to the hg19 or mm9 genome using bowtie 1.0.0 with 
standard parameters (Langmead et al., 2009). All genes with less than 10 mapped reads were removed 
from the analysis, after that RPKM values were calculated. The noise expression level was calculated 
from reads mapping to non-expressed regions. A gene was considered expressed, when the RPKM 
value was at least ten-fold higher than the noise level. Regulated genes were identified using the R-
package DEseq (Anders and Huber, 2010). Heatmaps were generated using hierarchical clustering in 
Cluster 3.0 (Hoon, 2002, Eisen et al., 1998) and visualized using TreeView 1.1.6r2 (Saldanha, 2004). 
4.10. Western blot analysis 
Cells were washed twice in ice-cold PBS, scraped into a falcon tube and spun down at 2700 xg for 1 min 
at 4 °C. Cells were resuspended in ten-fold volume of RIPA buffer and incubated on an overhead wheel 
for 30 min at 4 °C. After centrifugation at Rmax for 10 min at 4°C, the supernatant was mixed with 
protein loading buffer and denatured for 5 min at 100 °C. 
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Samples were separated on a 12 % SDS-polyacrylamide gel at 45 mA per gel for 1 – 2 h in SDS running 
buffer. After separation, proteins were transferred to a nitrocellulose membrane in blotting buffer 
using a semi-dry blotting chamber at 400 mA for 40 min at 4 °C. 
The membrane was washed in PBS and blocked in 5 % milk powder in PBS for 1 h at RT. After that the 
first antibody was added for 1 h at RT or overnight at 4 °C (α-Flag-M2, α-HA and α-Tubulin 1:5000). 
Then the membrane was washed three times in PBS for 20 min at RT, incubated with the second 
antibody in 5 % milk powder in PBS (α-Mouse-POD 1:5000) and washed again three times in PBS for 
20 min at RT. After that proteins were detected by incubation in detection buffer for 1 min and 
subsequent imaging. 
4.11. Chromatin immunoprecipitation 
5 x 106 cells either from stable cell lines with inducible Hey expression were induced with 50 ng/ml 
doxycycline for 48 h to obtain low level overexpression of Hey proteins or HEK293T cells were 
transiently transfected as described above. Non-induced or mock transfected cells were used as 
control. Chromatin immunoprecipitation was performed as described before (Wei et al., 2006). Briefly, 
the cells were fixed with 1 % paraformaldehyde for 10 min at RT. Fixation was stopped by adding 
glycine to 0.2 M for 5 min and cells were washed three times with ice-cold PBS and harvested. All 
subsequent steps were done at 4 °C. The cells were lysed in cell lysis buffer and spun down at 1000 xg 
for 5 min. The resulting pellet of nuclei was lysed in nuclei lysis buffer and sonicated using a Bioruptor 
Standard sonifier (for 20 min on “high” with 30 sec pulse and 30 sec break). Debris was removed by 
centrifugation. For immunoprecipitation, chromatin was diluted ten-fold with ChIP buffer. 1.5 ml of 
diluted chromatin was mixed with 40 µl 1:1 protein G agarose slurry (blocked for 4 h in ChIP buffer 
with 10 µg/ml BSA and 1 µg/ml Salomon sperm DNA), incubated for 1 h and spun down. The pre-
cleared supernatant was than incubated with 4 µg antibody overnight. After that 60 µl 1:1 protein G 
agarose slurry (in ChIP buffer) was added and incubated for 2 h. 
Then, the agarose beads were washed two times with low salt washing buffer, once with high salt 
washing buffer and four times with LiCl washing buffer. Elution was performed with 200 µl elution 
buffer at 68 °C for 30 min. The eluted chromatin was incubated with 0.8 mg/ml Proteinase K and PFA 
fixation was reversed by incubation at 68 °C overnight. The DNA was then purified using phenol-
chloroform extraction and precipitation and subsequently quantified using PicoGreen. 
For ReChIP the eluted chromatin was again diluted ten-fold with ChIP buffer and incubated with a 
second antibody, washed and eluted as described before. 
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4.12. Chromatin immunoprecipitation with high throughput sequencing 
For ChIPseq the same protocol as for ChIP was used in principle, but 2.5 x 108 cells were used and 10 µg 
of antibody in order to isolate enough enriched DNA. The amount of DNA was determined by 
PicoGreen measurement. 7–12 ng of ChIP enriched DNA were subjected to library preparation using 
the NEBNext ChIPseq sample preparation kit according to the manufacturer’s instruction. Briefly, DNA 
was end-polished with T4 DNA polymerase and kinase. After column purification, Illumina sequencing 
adaptors were ligated to the ChIP DNA fragments. DNA fragments ranging from 175 –225 bp were 
excised from an agarose gel using Qiagen gel extraction kit and subjected to 18 cycles of PCR 
amplification. The DNA fragments were assessed with the Experion DNA 1K kit and sequenced on an 
Illumina GAIIx platform.  
33 bp sequences were generated and mapped to the hg19 or mm9 genome using bowtie 1.0.0 
(Langmead et al., 2009) with standard parameters. Peaks were identified using MACS 1.4.1 (Zhang et 
al., 2008) using sequences from non-induced or mock transfected cells as control to identify the 
putative binding sites. All peaks with a maximum p-value of 10-5 and a minimum height of 10 
overlapping sequences were included. The unique mapping locations for each factor were used to 
generate the genome-wide intensity profiles, which were visualized using the Integrative Genomics 
Viewer (Thorvaldsdottir et al., 2013). PeakAnalyzer (Salmon-Divon et al., 2010) was used to annotate 
peaks and to calculate overlaps between different factors. Heatmaps were generated using seqMiner 
1.2.1 (Ye et al., 2011) with K-means raw clustering. The peak heights were normalized according to the 
1000 highest peaks within each sample. 
4.13. GO term analysis 
GO term analysis was performed with DAVID 6.7 (Huang da et al., 2009) using the functional annotation 
clustering method and allowing only to enrich for biological processes. Clusters were named based on 
interpretation of enriched GO annotations.  
4.14. Motif discovery  
The R-package motifRG (Yao) and MEME (Bailey et al., 2009) were used to identify binding motifs, 
using sequences +/-100 bp around the summit of the top 300 highest ranking peaks. Unrelated 
sequences with a similar distance towards TSS of genes lacking ChIPseq peaks and with similar GC 
distribution were selected and used as control/background. 
The software SMART (Veerla et al., 2010) was used to identify overrepresented binding motifs within 
sets of promoters.  
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5. Results  
5.1. Hey target genes HEK293 cells 
5.1.1. Expression of Hey proteins in HEK293 cells 
HEK293 cells have low level expression of endogenous Hey proteins. According to RNAseq data 
endogenous Hey1 ranked at position 837 of all expressed gene within the HEK293 transcriptome, 
expression of Hey2 and HeyL, which were at position 11 818 and 8 442 was around 20 fold lower. 
HEK293 cells, therefore, are capable to respond appropriately to overexpression of Hey proteins. 
However, the endogenous expression should be low enough to detect regulatory effects on target 
genes. 
 
Figure 9: Induction of Hey proteins in stable HEK293 cell lines 
Stable cell lines were induced with different doxycycline (dox) levels. After 48 h RNA and protein were harvested.  
(A) qRT-PCR shows fold-induction compared to endogenous levels at different doxycycline levels. 
(B) α-Flag Western blot shows Hey protein induction for different doxycycline levels. 
As there were no reliable Hey antibodies available, HEK293 cells that overexpress Flag tagged Hey 
proteins under control of a doxycycline inducible Promoter were used. Low level induction with 
50 ng/ml doxycycline resulted in a low overexpression in the range of 10 – 44 fold compared to 
endogenous level, whereas a high induction with 1 µg/ml doxycycline lead to a much higher 
overexpression (figure 9A). The higher fold change observed for Hey2 and HeyL is mainly due to the 
lower endogenous expression of HeyL. Doxycycline dependent induction could also be observed on 
protein level (figure 9B).  
5.1.2. Genome-wide Hey binding in HEK293 cells 
In order to identify genome-wide Hey binding sites, ChIPseq experiments were conducted. For each 
sample a comparable number of reads (15 – 16 million reads) was generated and on average 86 % of 
these could be mapped to the hg19 human genome (supplementary table 8). Using the before 
mentioned criteria (p-value ≤ 10-5 and peak height ≥ 10) 9 308 Hey1 and 9 128 Hey2 binding sites were 
identified within the HEK293 genome. For HeyL 60 922 binding sites were identified. 
c dox [ng/ml]:  0      5     50  100  500 1000
Hey1
Hey2
HeyL
c dox [ng/ml]:  0    5    15   50   200 1000
50 ng/ml dox 10 18 44
1000 ng/ml dox 223 1 677 27 713
A) B)Hey1 Hey2 HeyL
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Figure 10: Hey1, Hey2 and HeyL have overlapping binding properties in HEK293 cells 
ChIPseq data for Hey1, Hey2 and HeyL was generated by low level doxycycline induction (50 ng/ml for 48 h) of 
HEK293-Hey1, -Hey2 and HeyL cells, non-induced cells were used as control. 
(A) Venn-diagram showing the overlap between all identified binding sites. 
(B) Scatterplot showing the peak height in one sample plotted against the height in another sample. 
(C) This heatmap represents all identified Hey binding sites as a stack. The ChIPseq signal is shown in a window 
of 1 kb up- and downstream of the peak summit, which is centered in the middle of each column. The shading 
indicates the signal intensities. Binding sites were clustered in one cluster of shared binding sites and one cluster 
of unique HeyL binding sites. Also shown are the signals for polymerase II (POLII), histone H3 lysine 4 tri-
methylation (H3K4me3) and CTCF binding in HEK293 cells, which were derived from public databases. 
(D) The histogram shows the percentage of peaks within a certain distance to the closest transcription start site 
(TSS). 
(E) This diagram shows the percentage of peaks located within a certain genomic feature. 
(F) Shown are the average ChIPSeq signals for all shared peaks and for all unique HeyL peaks. 
There is a large overlap between DNA binding sites of different Hey proteins. About 85 % off all sites 
are shared between Hey1 and Hey2 and 92 % of those are also shared by HeyL. However, for HeyL 
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52 419 additional binding sites were identified (figure 10A). The peak height at shared binding sites is 
similar for Hey1 and Hey2, but higher for HeyL (figure 10B and F). The HeyL peak height is reduced at 
the HeyL uniquely bound sites. For these Hey1 and Hey2 show almost no enrichment. 
There are two groups of Hey bound sites, one contains the shared binding sites and one the HeyL 
uniquely bound sites (figure 10C). The shared sites are within close proximity to TSS (figure 10D). They 
are enriched for polymerase II binding and histone H3 tri-methylation at lysine 4 (H3K4me3), both are 
markers found at active promoters, meaning these genes are either poised for transcription or actively 
transcribed (figure 10C and F). These markers are not found at the unique HeyL sites, which are located 
more distal to TSS (figure 10C and G). All binding sites show CTCF binding.  
Shared binding sites are mainly located within proximal promoters or the first exon or intron of genes 
due to their close proximity to TSS (figure 10E). The relatively low percentage of peaks within the first 
exon is due to the much smaller size of exons compared to introns. HeyL unique sites are either in 
other introns further downstream or intergenic. 
5.1.3. Identification of Hey binding motifs 
Potential DNA binding motifs for Hey proteins were identified using the top 300 shared target sites 
and the top 300 unique HeyL bound sites. At shared sites, sequences near the peak summits are very 
GC-rich (around 85 %) due to their close proximity to TSS and the presence of CpG islands in their 
vicinity (figure 11A). At HeyL unique peaks GC-content is lower (around 62 %), but still above the 
average human GC-content. This is most likely due to the co-localisation with CTCF (figure 10C), which 
has a GC rich binding motif (CCGCGNGGNGGCAG) (Kim et al., 2007). 
Therefore, sequences with similar GC-distribution were used as control for motif discovery. De novo 
motif discovery at shared peaks yielded a class B E-box motif (CACGTG/CACGCG) as the preferred 
binding site (figure 11B). From the unique HeyL bound sites GC-rich motifs (GCCGC/CGCCC) were 
recovered, despite the use of a matching control. These non-palindromic motifs are untypical for 
binding of HLH factors and the relevance is unclear. There is a positive correlation between occurrence 
rate of the identified E-box motifs and Hey peak height at the shared peaks (figure 11C). DNA binding 
sites with high Hey binding peaks have a high occurrence rate of these motifs (65 %/ 40 %).  
Electrophoretic mobility shift assays with recombinant Hey1 protein expressed in E. coli demonstrated 
strong E-box binding (CACGTG) and efficient competition by the unlabeled oligonucleotide (figure 
11D). The two related oligonucleotides CACGCG and CGCGCG were also able to compete CACGTG 
binding, but to a lower extent. However, as there is a large number of binding sites without E-box 
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sequence, in vivo binding might have a more relaxed consensus sequence or may depend on other 
factors, e.g. indirect binding by interaction with other TF. 
 
Figure 11: In silico identified Hey binding motifs are bound by recombinant Hey1 protein in EMSA 
(A) Distribution of shared and unique HeyL DNA binding sites according to GC content. 
(B) The top two motifs for DNA binding identified by de novo motif discovery for the 300 highest shared and 
unique HeyL binding peaks. 
(C) Correlation between Hey1 peak height and motif occurrence rate at shared binding sites. 
(D) Recombinant MBP-Hey1 protein interacts with CACGTG. Binding of the biotin labelled CACGTG probe is 
competed increasingly by 5-, 15- and 50-fold molar excess of unlabelled CACGTG, CACGCG and CGCGCG-probes. 
The latter were the least effective. Shifted oligonucleotides are indicated by an arrow. 
5.1.4. Identification of Hey regulated genes 
We previously identified Hey1 and Hey2 regulated genes in HEK293 cells by microarray analysis (Heisig, 
2011, Heisig et al., 2012). To identify HeyL regulated genes in HEK293 we performed RNAseq. Around 
10 million reads were generated for both the doxycycline induced sample and the non-induced control. 
In average 88 % of the reads were mapped to the human genome (supplementary table 9). 
For all three Hey proteins we identified in total 661 genes, which are at least in one sample more than 
1.8-fold regulated. The number of Hey1 regulated genes is considerably smaller when using these 
criteria, which might be due to the higher endogenous expression of Hey1 compared to Hey2 and HeyL 
(figure 12A). When clustering all regulated genes, Hey1 and Hey2 regulated genes cluster together, 
with HeyL being more different (figure 12B). Regulation by HeyL was also generally stronger, which 
might be due to lower endogenous expression and higher induction of HeyL (figure 12B). However, as 
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the HeyL expression data was obtained by RNAseq and Hey1 and Hey2 expression data by microarray, 
these effects might be due to the application of different techniques and not related to the additional 
identified HeyL binding sites. Previously, regulation of these genes was confirmed by qRT-PCR in Hey 
overexpressing and knockdown cells (Heisig, 2011, Heisig et al., 2012). 
 
Figure 12: Hey target gene regulation in HEK293 cells 
(A) Number of down- and up-regulated genes from expression analysis in HEK293 cells 
(B) Hierarchical clustered heat map showing all genes which were more than 1.8-fold regulated in at least one 
sample. 
(C) For all more than 1.3-fold regulated genes the most enriched GO terms are given (cluster enrichment score 
> 1.3 are significant). 
By GO term analysis of regulated genes, we identified a striking overrepresentation of genes related 
to transcriptional control, developmental processes and apoptosis (figure 12C). The high occurrence 
of transcriptional control genes suggests that Hey proteins are higher up in the signaling hierarchy. 
Enriched developmental processes include limb and skeletal development, neurogenesis, and vascular 
development. These processes have previously been shown to be affected by Hey proteins and 
implicate them in a broad spectrum of developmental processes. HeyL regulated genes are also 
implicated in other processes including ubiquitination, oxidation, response to stress, and respiratory 
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chain. This also underlines that HeyL differs from Hey1 and Hey2 not only in its binding pattern but 
also in regulated target genes. 
 
Figure 13: Hey binding in Hey up- and down-regulated genes 
Boxplots depict the peak height at Hey1/2/L up- and down-regulated genes (≥ 1.3 fold) of binding sites near the 
TSS (-1 kb to +1 kb). Little arrows indicate up- or down-regulation. The median peak height, the total number of 
regulated, and the number of regulated genes with peak are given. 
We further correlated data of Hey regulated target genes with Hey DNA binding sites (figure 13). 
Especially genes with repression on mRNA level frequently have higher binding peaks close to their 
TSS. This supports the concept of Hey proteins being repressors. The observed up-regulation is most 
likely the result of indirect effects. 
5.1.5. Luciferase assays 
We used luciferase reporter constructs to functionally validate promoters of Hey regulated genes. For 
this purpose, we have chosen promoters with high Hey binding peaks and an E-box motif near the peak 
summit (figure 14A). Four promoters (Hey1, JAG1, BMPR1A and NEUROG3) were efficiently repressed 
in transient co-transfections with Hey1 (figure 14B and C). Co-transfection with an activator construct 
encoding a fusion of the Hey1 bHLH-Orange sequence with the vp16 activation domain resulted in 
increased luciferase expression. The DNA non-binding Hey1-RK3 mutant (Heisig et al., 2012), was not 
able to efficiently repress target promoters. In case of JAG1 a targeted mutation of the putative E-box 
motif (gggCACGCGtca to gggCAtca) abolished regulation by Hey1 and vp16-Hey1. 
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Figure 14: Functional analysis of Hey target promoters by luciferase assay 
(A) Hey1 ChIPseq signal for the JAG1, NEUROG3, BMPR1A and HEY1 genes. Orange lines indicate the closest 
potential Hey bond E-box motif under the peak summit. Open boxes indicate the fragment used in the luciferase 
assay and its position in bp relative to the TSS. For JAG1 a second luciferase construct with a mutated binding 
site was used (JAG1-Mut, deleted nucleotides underlined). 
(B) Schematic representation of different Hey1 variants used to determine the effect of Hey1 on luciferase-
promoter constructs. 
(C) Luciferase reporter analysis in HEK293T cells transiently transfected with reporter-constructs (JAG1, JAG1-
Mut, BMPR1A, Hey1 and NEUROG3) and Hey expression plasmids or empty vector control (set at 1). 
These data establishes Hey proteins as redundant repressors, which regulate other TF involved in 
various development processes. Hey proteins primarily bind to E-boxes close to TSS. 
5.1.6. Additional identified HeyL binding sites are no artefact 
The most striking difference in the ChIPseq data between the three Hey proteins are the many 
additional binding sites identified for HeyL. The HeyL overexpressing cell line was generated using a 
different construct and the fold-change induction was higher compared to Hey1 and Hey2. This raised 
the question whether the additional identified HeyL binding sites are just an artefact identified due to 
methodical differences. 
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Figure 15: Additional HeyL binding at EYA4 locus 
(A) Shown are the Hey1, Hey2 and HeyL ChIPseq signals for the EYA4 gene. All three Hey proteins bind to the 
proximal promoter region (peak 1). For HeyL there are three additional peaks further downstream (peak 2 – 4). 
(B) For Hey1 and HeyL ChIP experiments after induction with different doxycycline concentration were carried 
out. Shown is the enrichment for the four binding peaks (p1 – p4), with the shared peak p1 in red. 
(C) HEK293T cells were transiently transfected with pCS2p-Flag-Hey1 or -HeyL or pCS2p-HA-Hey1 or HeyL 
constructs. Enrichment was determined for the four binding peaks (p1 – p4). The shared peak p1 is indicated by 
a red box.  
To test whether the additional sites were only enriched for HeyL, because of higher expression, we 
conducted ChIP experiments with different induction levels of doxycycline for genes with a shared 
binding site at the promoter that functions as control and one or more unique HeyL binding sites 
further downstream. This was true for e.g. EYA4 (figure 15A), HIVEP and PXT1. For all three genes we 
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demonstrated that Hey enrichment is dose dependent: Higher induction correlates with higher 
enrichment at the binding site. However, although Hey1 binding could be observed at the shared sites, 
it could not be observed for the additional HeyL sites, even when Hey1 was highly induced with 1 µg/ml 
dox (figure 15B and supplementary figure 37A). 
To exclude the possibility that the additional unique HeyL sites are just an artefact resulting from the 
different constructs used to generate the HeyL cell line (ptol2 vector backbone for HeyL instead of 
p199 lentivirus for Hey1 and Hey2), we also conducted ChIP experiments using transiently transfect 
HEK293T cells with pCS2p constructs, constitutively expressing either HA or Flag tagged Hey proteins. 
Here, we observed enrichment for HeyL and Hey1 at the shared promoter peak. For the additional 
peaks at the EYA4 gene the enrichment for Hey1 was only low, whereas the enrichment for HeyL was 
about 15-fold stronger. This shows that HeyL binding of additional sites is not caused by use of different 
vector backbones (figure 15C). The same is true for the HIVEP and the PXT1 genes (supplementary 
figure 37B). 
These results show that the additional binding sites identified for HeyL are predominantly bound by 
HeyL and this is an actual difference to the other two Hey proteins and not just an experimental 
artefact. 
5.1.7. Additional HeyL binding sites are not bound by Hey heterodimers 
Hey proteins are bHLH factors which bind DNA as dimers. They are able to form homo- as well as 
heterodimers (Iso et al., 2001b, Leimeister et al., 2000a, Fischer et al., 2007). We did not observe 
enrichment for Hey1 at the additional HeyL bound sites when overexpressing Hey1 on its own. This 
indicates that either only HeyL homodimers bind these additional sites or that the expression of 
endogenous HeyL was not sufficient enough to observe an enrichment for Hey1-HeyL heterodimers. 
As the endogenous expression of HeyL was low, HEK293T cells were co-transfected with Flag tagged 
Hey1/2/L and HA tagged HeyL. Flag-ChIP was performed followed by another HA-ChIP (ReChIP) to 
identify bound dimers. 
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Figure 16: Heterodimer binding at EYA4 gene 
HEK293T cells were transiently co-transfected with pCS2p-HA-HeyL and pCS2p-Flag-Hey1, -Hey2 or -HeyL 
constructs. Control cells were either only transfected with pCS2p-Flag-Hey1 or -HeyL or empty pCS2p-Flag 
(mock). First a Flag-ChIP was carried out for all samples, after that half of the eluted chromatin was used for the 
HA-ReChIP. The enrichment was determined for the Flag-ChIP and the HA-ReChIP samples for the four binding 
peaks (p1 – p4). The shared peak p1 is indicated by a red box. 
After the Flag-ChIP, enrichment for all three Hey proteins was observed at the shared site of the EYA4 
gene (figure 16 p1). For Hey1 or Hey2, however, no enrichment was observed at the additional unique 
HeyL bound sites (p2 – p4), even when HeyL was co-transfected. These results are very similar to those 
from the stable cell lines and indicate that the unique HeyL bound sites are neither bound by Hey1-
HeyL nor by Hey2-HeyL heterodimers.  
After the second ChIP against the HA-tagged HeyL (ReChIP), similar enrichment for HeyL was observed 
for all three co-transfections with Flag-Hey1/2/L at the shared locus (p1). That means HA-tagged HeyL 
was bound in combination with Flag-tagged Hey1, Hey2 or HeyL. This indicates that HeyL-HeyL 
homodimers, as well as Hey1-HeyL and Hey2-HeyL heterodimers bind to the shared locus (p1). For the 
additional peaks (p2 – p4) only the sample transfected with Flag-HeyL showed enrichment for HA-HeyL 
after HA-ReChIP. This suggests that only HeyL-HeyL homodimers bind to the additional HeyL binding 
sites (p2 – p4). 
Control cells only transfected with Flag-tagged Hey1 or HeyL demonstrated enrichment after the Flag-
ChIP, but not after HA-ReChIP and mock transfected cells showed no enrichment in either the Flag-
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ChIP or the HA-ReChIP, as expected. Very similar results were obtained for HIVEP and PXT1 
(supplementary figure 38). 
5.1.8. Binding of HeyL-Hey1 chimeric proteins 
Having found that HeyL in contrast to Hey1 and Hey2 is able to bind additional sites, we cloned chimeric 
proteins. As the bHLH and the Orange domain are largely conserved between all three Hey proteins, it 
was unlikely that differences within that region were the cause for binding of additional sites. 
Therefore, the C- and N-terminal parts of the HeyL protein were replaced with the matching parts from 
Hey1 (figure 8 and 17B). The conserved region containing bHLH and Orange domain was in both cases 
derived from HeyL. 
 
Figure 17: Binding of chimeric Hey1-HeyL proteins at EYA4 locus 
(A) HEK293T cells were transfected with pCS2p-Flag-Hey constructs expressing either Hey1, HeyL or two chimeric 
proteins containing either the N-terminal part of HeyL and the C-terminal part of Hey1 (HeyL-1) or vice versa 
(Hey1-L). The enrichment was determined for the four binding peaks (p1 – p4) at the EYA4 gene. The shared peak 
p1 is indicated by a red box. 
(B) The two used chimeric proteins are depicted here. An α-Flag Western blot was performed. b = basic domain; 
HLH = helix loop helix domain; 
ChIP experiments showed that only the chimeric protein containing the C-terminal part of HeyL was 
enriched at the additional sites at the EYA4 gene (figure 17A). The same was true for the additional 
sites at HIVEP and PXT genes (see supplementary figure 39). The shared binding sites were bound by 
both chimeric variants, as well as by Hey1 and HeyL. This demonstrates that the ability of HeyL to bind 
the additional sites depends on the C-terminal region of the HeyL protein. 
5.1.9. Binding behavior of the HeyL DNA non-binding mutant 
Hey proteins can directly interact with DNA. With their basic domain they bind to an E-box motif. As 
the additional sites were only bound by HeyL and no E-box motif could be recovered, we were asking 
the question whether this is a direct interaction with DNA or whether HeyL binds to these sites via an 
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interaction partner. Therefore, we generated a HeyL binding mutant containing three point mutations 
within the basic domain converting three arginine residues that presumably interact with DNA to lysine 
(figure 18B). The same mutations were previously introduced into Hey1 and abolished direct DNA 
binding completely (Heisig et al., 2012). In case additional HeyL binding sites are only bound indirectly 
via an unknown interaction partner, this mutation should be without an effect on HeyL binding to these 
sites. Binding to the shared binding site, which most likely results from direct DNA binding, should be 
abolished. 
 
Figure 18: Binding of Hey1-L-RK3 nonbinding mutant at EYA4 locus 
(A) HEK293T cells were transfected with pCS2p-Flag-Hey constructs expressing Hey1, the chimeric Hey1-L protein 
or the Hey1-L-RK3 mutant, with 3 point mutations in the binding sites, abolishing DNA binding. The enrichment 
was determined for the four binding peaks (p1 – p4) at the EYA4 gene. 
(B) The used binding mutant is depicted here. An α-Flag Western blot was performed. b = basic domain; HLH = 
helix loop helix domain; 
ChIP experiments demonstrated that the binding mutant Hey1-L-RK3 is not able to bind to any of the 
analyzed DNA binding sites. This shows that a direct interaction of the DNA binding domain is required 
for all HeyL binding sites including the unique HeyL bound sites (figure 18A and supplementary figure 
40). Binding of these sites may still depend on a direct interaction partner that interacts with the C-
terminal part of HeyL but not with the C-terminal parts of Hey1 or Hey2. Nevertheless, no factors have 
been described so far, which only interact with HeyL but not Hey1 or Hey2. 
5.1.10. Validation of HeyL differently regulated genes 
In HEK293 cells we identified 661 genes with more than 1.8-fold regulation (figure 12B). 332 genes 
were differently regulated by HeyL compared to Hey1 and/or Hey2 (≥ 1.8-fold) and 329 were similarly 
regulated (< 1.8-fold). 
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Figure 19: Validation of HeyL differently regulated genes 
(A) Shown are differently regulated genes, which are highly expressed in HEK293 cells (> 20 RPKM) and have at 
least one additional HeyL binding site within their gene body. Indicated is also whether a gene has an additional 
shared peak at the promoter. Genes marked in bold were validated by qRT-PCR. 
(B) qRT-PCR results for the in (A) indicated genes. Here an additional stable HeyL cell lines was used: the by 
lentiviral transfection generated EF1TA cell line. Cells were induced with 1 µg/ml doxycycline for 48 h and 
compared to non-induced control cells, transfected cells were compared to pCS2p-Flag mock transfected control 
cells. 
(C) Shown is the overexpression of Hey1, Hey2 and HeyL in the cell lines used. 
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These two sets of target genes were used to search for differences in HeyL DNA binding. However, no 
significant differences in binding were identified between the two groups, neither for proximal shared 
binding sites nor for distal unique HeyL binding sites (supplementary figure 41). To confirm that HeyL 
overexpression really results in additional regulation compared to Hey1 and/or Hey2, regulation was 
confirmed by qRT-PCR for some of the differently regulated genes. Therefore, especially highly 
expressed genes (according to RNAseq data) and genes with at least one additional HeyL binding site 
were chosen (figure 19A).  
Seven genes were analyzed by qRT-PCR, four HeyL down-regulated and three HeyL up-regulated genes. 
All down-regulated genes were significantly down-regulated in the same cell-line that was used for the 
RNAseq (HEK293-ptol2-HeyL), but only one was also significantly down-regulated in another stable 
HeyL cell line (HEK293-EF1TA-HeyL; figure 19B). However, this was most likely due to the fact that the 
induction of HeyL was much lower in the HEK293-EF1TA-HeyL cell line (figure 19C). Therefore, also 
transiently transfected HEK293T cells were used for validation. Here the induction of HeyL was much 
stronger (figure 19C) and it was possible to confirm the regulation for all four down-regulated genes 
(figure 19B). This down-regulation was not observed for Hey1 or Hey2. Up-regulation could also be 
confirmed, although regulation was not always significant. 
These results show that there are indeed genes, which are differently regulated by HeyL, and it was 
possible to confirm this regulation also with transiently transfected cells. However, the large number 
of additional HeyL binding sites and the fact that there is no difference in HeyL binding between 
differently and similarly regulated genes raises doubt that the function of these additional HeyL DNA 
binding sites is additional transcriptional regulation. Therefore, the functional relevance of these 
unique HeyL bound sites remains unclear. 
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5.2. Hey target genes in murine ES cells and cardiomyocytes 
5.2.1. Efficient differentiation of murine ES cells into cardiomyocytes 
Besides HEK293 cells, ESC and in vitro differentiated CM were used to study Hey target genes and their 
regulation. This differentiation system is more relevant for the previously observed cardiac phenotype. 
Two murine ESC lines with a MHC promoter driven neomycin resistance and doxycycline inducible 
Hey1 or Hey2 expression were used. 
 
Figure 20: Efficient in vitro CM differentiation 
(A) Schematic representation of the differentiation protocol of the murine ESC line CM7/1 into CM. Images were 
taking from the ES-Hey1 cell line. LIF = Leucemia inducing factor; 
(B) Immunofluorescence shows positive staining for cardiac troponin I and meromyosin in in vitro differentiated 
CM. 
(C) qRT-PCR results showing the induction of Hey1 and Hey2 on mRNA and α-flag Western blot demonstrating 
induction on protein level after induction with 1000 ng/µl doxycycline for 48 h in ESC. 
ESC were maintained and expanded in ESC medium containing LIF, a GSK3 and a MEK inhibitor for at 
least 5 days before differentiation was started (figure 20A). During differentiation, cells were grown 
without these factors on shaking petri dishes. They formed EB and differentiated into all three germ 
layers. At day 10 the first EB started to contract spontaneously, indicating that CM were present. At 
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this stage, selection of CM was started by addition of G418 for 5 days. Many dead cells appeared in 
the medium and EB became roughly shaped due to dying cells without MHC promoter activity (figure 
20A). At day 15 most EB were contracting. They were dissociated and plated as CM monolayer resulting 
in a very pure CM population. These CM stained positive for typical marker genes, like cardiac troponin 
I and meromyosin (figure 20B). It was possible to induce Hey1 or Hey2 expression in these cells via 
doxycycline (figure 20C). 
 
Figure 21: Expression of pluripotency, cardiac markers, and endogeneous Hey during differentiation 
(A, B) RNA was isolated from non-induced ES-Hey1 cells before differentiation (ESC), at days 3, 5, 7, 9, 12, 14, 15 
of differentiation and from differentiated CM from three independent differentiations. Lines show the mean 
change compared to ESC, standard deviations are shown as transparent fields surrounding the graphs. 
C) lg fold change between non-induced Hey1 or Hey2 expressing ESC and differentiated CM for all more than 
two-fold regulated genes. They are sorted according to their regulation. Indicated are the four most enriched 
GO-terms for the 1000 most down- and up-regulated genes. 
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During differentiation, expression of the pluripotency markers Sox2, Nanog and Oct4 was greatly 
reduced and typical cardiac markers were highly enriched like the ventricular and atrial variants of 
myosin light chain 1 and 2 (Mlc1, Mlc2; figure 21A). A decline in stem cell markers was visible from day 
3 onwards, the first time point measured after removement of LIF from the cell culture medium. 
Cardiac markers were highly enriched later during differentiation (after day 7/9; figure 21A), which 
coincides with the first contracting EB, observed at day 9. After that CM were enriched via selection 
with G418 and expression of cardiac markers was highly increased.  
Endogenous Hey was expressed to a low, but detectable extend in the ESC (figure 21B). Expression 
increased during differentiation and peaked around day 9 and declined again. The decline coincided 
with the selection of CM via G418. In derived CM, Hey expression was only slightly elevated compared 
to ESC, with HeyL showing the highest elevation. All presented results were obtained from the Hey1 
expressing cell line (ES-Hey1), but similar results were also obtained for the Hey2 expressing cell line 
(ES-Hey2; data not shown). 
To further confirm the identity of the differentiated cells, gene expression between non-induced ESC 
and CM was compared. For the Hey1 expressing cells, 8 732 genes were more than two-fold differently 
expressed between ESC and CM, while 7 551 genes were differently expressed for Hey2 (figure 21C). 
Genes that were higher expressed in ESC are associated with GO terms like “negative regulation of 
differentiation” or “embryonic development”. Genes higher expressed in CM were associated with 
“muscle organ development” and “heart contraction”. 
 
Figure 22: Total Hey level with and without induction during differentiation 
RNA was isolated from non- and continuously induced (1 µg/ml dox from day -2 until cells were harvested) ES-
Hey1 and ES-Hey2 cells before differentiation (ESC), at days 3, 5, 7, 9, 12, 14, 15 of differentiation and from 
differentiated CM from three independent differentiations. Lines show the mean change compared to 
non-induced ESC, standard deviations are shown as transparent fields surrounding the graphs. 
It was also tested whether prolonged overexpression of Hey1 and Hey2 has an effect on differentiation. 
To this aim, cells were cultured for the entire time of differentiation with 1000 ng/µl doxycycline 
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induced compared to endogenous levels (figure 22), but no differences in differentiation efficiency, 
cell morphology or marker expression (e.g. atrial vs. ventricular markers) were observed 
(supplementary figure 42). 
5.2.2. Genome-wide Hey binding in murine ES cells and cardiomyocytes 
The above presented in vitro differentiation system was used to identify Hey bound regions in ESC and 
differentiated CM by ChIPSeq experiments. Therefore, a comparable number of reads (13 – 19 million 
reads) was generated for each sample and on average 76 % of these could be mapped to the mm9 
mouse genome (supplementary  table 10 and 11). However, only 52 % of the CM Hey2 sample and 
43 % of the CM Hey2 control reads could be mapped to the mm9 genome due to the presence of 
adapter dimers in the sequencing library. 
54 613 and 31 014 DNA binding sites were identified for Hey1 and Hey2, respectively, within the ESC 
genome and a lower number of 17 874 and 20 498 binding sites within the CM genome (figure 23A). 
There is a large overlap between Hey1 and Hey2 binding sites in ESC (44 % compared to Hey1 and 78 % 
compared to Hey2) and in CM (73 % and 64 %). There is also a large overlap between ESC and CM, in 
total around 7 974 peaks are shared between Hey1 and Hey2 in both cell types (figure 23A).   
The main difference between the samples is that for both Hey proteins more DNA binding sites were 
present in the ESC. This difference is also visible from scatterplots comparing the peak height of two 
samples (figure 23B). Here, the correlation between Hey1 and Hey2 in the same cell type is higher 
(0.92 and 0.93) than the correlation between ESC and CM (0.42 – 0.51). Focusing on Hey binding near 
TSS of annotated genes, revealed that Hey1 and Hey2 largely bind to the same genes, but that there 
are more Hey bound genes in ESC than in CM (figure 23C). Hey binding sites are mainly located within 
proximal promoters or the first exon or intron of genes due to their close proximity to TSS (figure 23D 
and E).  
The observed redundancies between Hey1 and Hey2 and the genomic distribution of binding sites is 
also comparable to the results obtained for Hey1/2/L in HEK293 cells (figure 10A). 
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Figure 23: Hey1 and Hey2 have overlapping binding properties in murine ESC and CM 
ChIPseq data for Hey1 and Hey2 was generated by low level doxycycline induction (50 ng/ml for 48 h) of ES-Hey1 
and -Hey2 cells and differentiated CM, non-induced cells were used as control. 
(A) Venn-diagram showing the overlap between all identified binding sites. 
(B) Scatterplot showing the peak height in one sample plotted against the peak height in another sample at all 
TSS. The given numbers are the Pearson's product-moment coefficient. 
(C) This heatmap represents all murine TSS as a stack. The ChIPseq signal is shown in a window of 1 kb up- and 
downstream of each TSS. The shading indicates the signal intensity. Promoters were clustered in three groups: 
ESC and CM bound, ESC bound, and unbound promoters.  
(D) The histograms show the percentage of peaks within a certain distance to the closest TSS. 
(E) This diagram shows the percentage of peaks located within a certain genomic feature. 
A) Overlap Hey1 & Hey2, ESC & CM peaks C) Heatmap of Hey binding sites
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5.2.3. Hey gene regulation in ES cells and cardiomyocytes 
In order to identify Hey regulated genes, microarray analysis was previously performed in ESC (Heisig, 
2011) and RNAseq was performed in CM. In CM between 8 and 23 million reads were generated 
(supplementary table 12). In average 90 % of the reads were mapped to the mouse genome. We 
identified in total 660 genes, which are more than 1.8-fold regulated in at least one sample. 
 
Figure 24: Hey regulated genes in ESC and CM 
ES-Hey1 and ES-Hey2 cells were induced with high levels of doxycycline (1 µg/ml for 48 h), and non-induced cells 
were used as control. In ESC gene expression was detected by microarray and in CM by RNAseq. 
(A) Venn-diagram showing the overlap between Hey1 and Hey2 more than 1.8-fold regulated genes. 
(B) Hierarchical clustered heatmap shows all genes that are more than 1.8-fold regulated in at least one sample. 
Given are the percentages of genes, which are similar or differently regulated by Hey1 and Hey2. 
(C) Validation of selected target genes by qRT-PCR. Significantly regulated genes are printed in bold. As control 
cells without the inducible Hey constructs were also doxycycline treated and compared to untreated controls. 
All values are based on triplicates. 
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The number of Hey1 and Hey2 regulated genes in ESC and CM was comparable (figure 24A). Most 
genes were similarly regulated by Hey1 and Hey2 in ESC (87 %, figure 24B). In CM approximately half 
of the regulated genes were similarly regulated (56 %; figure 24B). This was despite the small overlap 
between the 1.8-fold Hey1 and Hey2 regulated genes per se (n = 44 in ESC and n = 8 in CM; figure 24A). 
However, many genes that were 1.8-fold regulated by only one Hey protein were similarly but to a 
lower extent regulated by the other Hey protein. 
qRT-PCR confirmed most genes that were similarly regulated (14 out of 16 significant regulated), 
whereas confirmation of genes only regulated by either Hey1 or Hey2 was only possible to a much 
lower extent (2 out of 9; figure 24C). This was also true for the Hey up-regulated genes. Therefore, I 
focused my analysis on genes which were similarly regulated by Hey1 and Hey2 (n = 416), as they are 
more confident targets by using the results from Hey1 and Hey2 as “duplicates”. 
5.2.4. Differences in Hey gene regulation between ES cells and cardiomyocytes 
My analysis focused on differences in Hey target gene regulation between ESC and CM. Therefore, I 
categorized all regulated genes in four main groups (figure 25): (1) genes up-regulated in both cell 
types, (2) genes down-regulated in CM, (3) genes down-regulated in ESC, and (4) genes down-
regulated in both cell types. I used these four sets of genes in order to investigate, why some genes 
were only regulated in one cell type, despite most of the genes being similarly expressed in both cell 
types, whereas other genes were regulated in both cell types. 
Among Hey regulated genes were many TF involved in various developmental processes, cell cycle, 
apoptosis, and proliferation (figure 25). The four clusters of regulated genes were quite similar in that 
regard. However, genes involved in cell migration were particular enriched within the cluster of ESC 
down-regulated genes, while genes involved in cell cycle were enriched within the cluster of CM down-
regulated genes. 
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Figure 25: Differences between Hey regulated genes in ESC and CM 
Hierarchical clustered heat map showing all genes, which are more than 1.8-fold regulated in at least one sample 
(ESC or CM) and similar regulated by Hey1 and Hey2. Genes are divided in four main groups. For each cluster the 
6 most enriched GO terms are given (values > 1.3 are significant). The dashed box indicates a group of more 
concisely in CM up-regulated genes. 
5.2.5. Correlation between gene regulation and Hey peak height 
In order to see whether the observed regulations were the result of Hey promoter binding, I analyzed 
Hey binding sites within the regulated genes. For each cluster I calculated the average Hey binding 
peak height within the proximal promoter of the corresponding gene. In ESC the average Hey1 and 
even more so the Hey2 peak heights are higher in genes, which are down-regulated compared to up- 
or non-regulated genes (figure 26A). This was previously also observed for HEK293 cells, where up-
regulated genes have less and lower Hey binding sites compared to down-regulated genes (figure 13). 
This indicates that there are less direct Hey targets among up-regulated genes. 
When looking at CM, the same pattern can be observed as in ESC with up-regulated genes having lower 
peaks than down-regulated genes (figure 26A). Genes that are specifically down-regulated in CM have 
also increased Hey binding peaks within their promoters, which is a significant increase compared to 
ESC. This further supports the idea that whether a gene is down-regulated by Hey dependents on the 
Hey binding to its promoter. However, genes, which are only down-regulated in ESC, do not have 
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reduced binding peaks in CM. For these genes other mechanisms seem to prevent Hey repression in 
CM. 
 
Figure 26: Average Hey binding signal in clusters of Hey regulated genes 
A) For the four identified clusters of Hey regulated genes, the average Hey peak height at the proximal promoter 
(-1kb/+1kb) was calculated. For genes with several Hey binding peaks in their promoter the highest peak was 
considered. Peak height was normalized according to the 1000 highest peaks within each sample. A student’s 
t-test was performed to identify significant differences (p-value ≤ 0.01 **; p-value ≤ 0.05 *; p-value > 0.05 ns). 
B) The average Hey peak height and regulation was calculated for sets of 50 genes with similar regulation. The 
coefficient of determination (R²) was calculated for a linear regression. 
For the same set of genes the correlation between peak height and fold regulation was calculated, to 
find out if there is a quantitative relation between Hey binding and regulation. This is the case for the 
in ESC down-regulated genes (figure 26B). Here the correlation is extremely strong. The slope for the 
Hey2 regulated genes is steeper compared to Hey1, similar to the greater difference observed for Hey2 
between the different groups of regulated genes (figure 26A). There is no robust correlation between 
Hey peak height and up-regulation. 
In CM the correlation for both down- and up-regulated genes is poor (figure 26B). This indicates that 
the down-regulation in ESC is mainly the direct result of Hey binding, whereas in CM additional 
mechanisms influence down-regulation of target genes. Up-regulation is mainly the result of indirect 
effects in both cell types.  
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5.2.6. Investigation of possible Co-factors involved in Hey target gene regulation 
In order to identify co-factors involved in the regulation of Hey target genes, over-represented binding 
motifs within the promoter regions of the regulated genes were identified. Then the expression data 
was used to identify binding factors, which are expressed in the used cellular system. 
 
Figure 27: Enriched binding motifs in promoters of Hey regulated genes 
Shown are the 15 most significantly enriched binding motifs within the promoters (-1kb/+1kb) of all Hey 
regulated genes. Colors indicate whether binding factors are expressed in CM (red), ESC (blue), both (grey) or 
not expressed (white). 
Interestingly SRF and NKX25 binding motifs are overrepresented for all Hey regulated genes (figure 27). 
These motifs are bound by the serum response factor (Srf) and NK2 homeobox 5 (Nkx2-5). Both are 
cardiac specific TF, which are known to be involved in cardiac development, and are highly expressed 
in CM but not in ESC. In order to identify a possible correlation between Hey regulation and these 
factors, the average peak height for these TF in Hey regulated gene clusters was analyzed in a similar 
way as previously done for Hey binding. ChIPseq data for these factors and Gata4 previously generated 
in HL1 cells (murine CM cell line) was derived from publicly available data (He et al., 2011). There is no 
ChIPseq data for ESC available as these factors are not expressed in these cells. 
 
Figure 28: Average Srf, Nkx2-5 and Gata4 binding signal in clusters of Hey regulated genes 
A) For the four identified clusters of Hey regulated genes, the average Srf, Nkx2-5 and Gata4 peak height in HL1 
cells was calculated. For genes with several binding peaks the highest peak was considered. Peak height was 
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normalized according to the 1000 highest peaks within each sample. A student’s t-test was performed to identify 
significant differences (p-value ≤ 0.01 **; p-value ≤ 0.05 *; p-value > 0.05 ns). 
B) The average ratio between Hey peak height and the sum of Srf, Nkx2-5 and Gata4 peak heights was calculated 
for sets of 50 genes with similar regulation in CM. The coefficient of determination (R²) was calculated for a linear 
regression. 
All three factors are enriched for genes that are down-regulated by Hey in ESC but not in CM: For Srf 
and Nkx2-5 this enrichment is significant (figure 28A). As these factors are not expressed in ESC, they 
cannot interfere with Hey regulation in these cells. However, as they are expressed in CM it appears 
as they could counteract possible down-regulation by Hey promoter binding. Genes that are repressed 
by Hey in CM are less bound by these factors.  
There is a direct correlation between the ratio of Hey binding and binding of these factors with the 
observed down-regulation in CM (figure 28B). These results indicate that these three factors combined 
with Hey could play a role in achieving a cell type and gene-specific regulation of Hey target genes in a 
dose dependent manner. 
5.2.7. Influence of Hey binding on histone acetylation 
There are several histone markers known, which are associated with active promoters like histone 
methylation (H3K4me3) and histone acetylation (H3K27ac) (McLeay et al., 2012, Karlic et al., 2010). 
Therefore, public available histone modification data from the ENCODE project generated from murine 
ESC (E14 cell line), embryonic hearts (E14.5) and adult hearts was analyzed (ENCODE, 2011).  
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Figure 29: Average H3K4me3 and H3K27ac in clusters of Hey regulated genes 
For the four identified clusters of Hey regulated genes, the average (A) H3K4me3 and (B) K3K27ac enrichment in 
E14 ESC, E14.5 embryonic hearts, and adult hearts at the promoter (-1 kb/+1kb) was calculated. In all cases the 
highest enrichment within the promoter was used. A student’s t-test was performed to identify significant 
differences (p-value ≤ 0.01 **; p-value ≤ 0.05 *; p-value > 0.05 ns). For the up-regulated genes an additional more 
confident group including only genes which are up-regulated in CM was also analyzed. The results are indicated 
by dashed lines. For H3K4me3 no significant differences were observed. 
For the H3K4me3 no significant differences could be identified between different clusters of Hey 
regulated genes or between cell types (figure 29A). However, for H3K27ac significant differences exist 
between the groups of Hey regulated genes: Genes which are down-regulated show a reduced 
promoter acetylation compared to up-regulated genes in ESC (figure 29B). This hints that Hey binding 
influences histone acetylation. Acetylation at promoters of genes, which are only down-regulated in 
ESC, is increased in murine hearts: in E14.5 embryonic hearts and even more in adult hearts. This higher 
acetylation correlates with elevated Srf, Gata4 and Nkx2-5 binding peaks for these genes (figure 28A).  
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Genes, which are only down-regulated in CM have a slightly lower acetylation in embryonic and adult 
hearts compared to ESC, but the effect is less pronounced. However, acetylation is much lower 
compared to the group of genes, which are only down-regulated in ESC. This is also true for genes, 
which are down-regulated in both cell types. For these genes there is no difference in acetylation 
between ESC and CM.  
For the up-regulated genes acetylation is higher in ESC. In CM it appears similar to the down-regulated 
genes, which is not in agreement with the idea that Hey down-regulated genes have a reduced 
acetylation compared to up-regulated ones. However, among the cluster of up-regulated genes, there 
are many which are only consistently up-regulated in ESC, but not in CM (figure 25). This could cause 
a dilution of effects for this group in CM. To test whether this is the case, I reanalyzed the up-regulated 
genes, taking only genes into account that are consistently up-regulated in both cell types (dashed box 
in figure 25). For this group the average acetylation in ESC is nearly unchanged, but in embryonic and 
adult heart a higher average acetylation is observed (dashed box in figure 29B).  
5.2.8. Diversity among Hey regulated genes  
Hey down regulated genes usually have higher Hey binding peaks within their promoter regions and 
their promoters have less histone acetylation, which supports the idea, that Hey proteins recruit 
Histone deacetylases (Hdacs) to repress target genes. These affects ale may be overwritten in CM by 
binding of cardiac activators such as Srf, Nkx2-5 and Gata4, which have in average increased binding 
in genes only down-regulated in ESC. This would results in a higher level of histone acetylation in CM 
(as observed) and might prevent Hey mediated down-regulation. All these conclusions were drawn 
from focusing on average binding intensities for groups of regulated genes. However, there are many 
individual genes that behave differently from the average trend suggested. This can be seen in the 
heatmap of figure 30, showing regulation and binding signals for individual genes. 
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Figure 30: Heatmap showing Hey regulation, Hey, Srf and Nkx2-5 and Gata4 binding, and histone acetylation 
Lanes 1 – 4 show the hierarchical clustered heat map of genes that were more than 1.8-fold regulated in at least 
one sample (ESC or CM) and similar regulated between Hey1 and Hey2. Genes are divided in four main groups. 
Lanes 5 – 8 show Hey binding to the promoters of these genes in ESC and CM. Lanes 9 – 11 show Srf, Nkx2-5 and 
Gata4 in HL1 CM and lanes 12 – 14 show H3K27ac in E14 ESC, in E14.5 murine embryonic hearts and in murine 
adult hearts. 
Concentrating on the heatmap the same general trends as described previously can still be seen, but 
there is great diversity within the four groups for individual genes. Generally, higher and more Hey 
binding sites are coherent with down-regulation of genes, but there are many down-regulated genes, 
which do not have any Hey binding sites in their promoters (figure 30 lanes 5 – 8). Further examples 
would be the higher Srf, Nkx2-5 and Gata4 binding observed in CM (figure 30 lanes 9 – 11) as well as 
the histone acetylation in murine hearts (figure 30 lanes 13 – 14) for genes only down-regulated in 
ESC. 
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Apart from the cardiac activators analyzed here, we suppose additional factors and mechanism to be 
most likely involved, which also influence regulation of individual genes. This may result in a much 
more complex regulatory mechanism and gene and cell type specific regulation. However, the general 
trends remain visible, suggesting that the factors analyzed here might be the main contributor for the 
here observed regulation by Hey proteins. 
5.2.9. Validation of Hey binding, promoter acetylation and target gene regulation 
In order to confirm the previous findings, additional ChIP experiments for selected sample genes from 
each cluster were conducted. The selected genes are: Krt7, which is up-regulated, Cxcr4, which is 
down-regulated only in CM, Zfhx3 and Jag1, which are down-regulated only in ESC and Bcl11a, which 
is down-regulated in both cell types. 
5.2.9.1. Krt7 - a Hey up-regulated gene 
The profile for the up-regulated Krt7 gene does not give much information, it does not reveal any Hey 
binding site and is therefore, like many up-regulated genes, no direct Hey target (figure 31A). 
 
Figure 31: Validation of the Hey up-regulated Krt7 gene 
A) Given are the ChIPSeq profiles for ESC and CM. The peak height is normalized to the 1000 highest peaks within 
each sample. H3K27ac is shown as heatmap for E14 ESC, mouse E14.5 embryonic and adult hearts. Values scale 
from 0 (white) to 5 (black) 
B) qRT-PCR results are derived from three independent biological samples (except CM-CM7/1 control – only one 
sample). The delta delta CT value to a non-induced or wild-type control is given. Error bars indicate the standard 
deviation. A student’s t-test was performed to identify significant differences (p-value ≤ 0.01 **; p-value ≤ 0.05 
*). 
C) delta delta CT value of the non-induced or wild-type controls compared to ES-Hey1. 
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The promoter shows low levels of acetylation in ESC and CM, which are comparably. The up-regulation 
was confirmed by qRT-PCR in ESC and CM (figure 31B). It was not possible to confirm the observed 
regulation in murine hearts of Hey2 KO or Hey1 overexpressing mice. Only in E14.5 embryonic hearts 
a slight up-regulation was observed when Hey1 was overexpressed (figure 31B).  
5.2.9.2. Cxcr4 – a Hey cardiomyocyte specific down-regulated gene 
The Cxcr4 gene, which is down-regulated in CM, shows Hey binding peaks in ESC and CM (figure 32A). 
The promoter is highly acetylated especially in ESC around the Hey binding peaks, but acetylation is 
reduced in CM.  
 
Figure 32: Validation of the in CM by Hey down-regulated gene Cxcr4 
A) Given are the ChIPSeq profiles for ESC and CM. The peak height is normalized to the 1000 highest peaks within 
each sample. H3K27ac is shown as heatmap for E14 ESC, mouse E14.5 embryonic and adult hearts. Values scale 
from 0 (white) to 5 (black) 
B) qRT-PCR results are derived from three independent biological samples (except CM-CM7/1 control – only one 
sample). The delta delta CT value to a non-induced or wild-type control is given. Error bars indicate the standard 
deviation. A student’s t-test was performed to identify significant differences (p-value ≤ 0.01 **; p-value ≤ 0.05 
*). 
C) delta delta CT value of the non-induced or wild-type controls compared to ES-Hey1. 
D) ChIP results from two replicates at four time points during CM differentiation for Hey1 and Hey2 over-
expressing cells. Flag-ChIP was performed after 48 h of low level doxycycline induction (50 ng/µl). ChIP against 
Hdac2 and H3ac was performed after 48 h of high level induction at which regulation was observed (1 µg/ml). 
Values below 1 % are not shown. 
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The observed down-regulation was confirmed in CM (figure 32B). Here, base-line expression of Cxcr4 
is higher compared to ESC (figure 32C). Hey binding was proven by independent ChIP experiments. Hey 
is bound to the Cxcr4 promoter in ESC and during differentiation and is increased in differentiated CM 
(figure 32D). Histone deacetylases (Hdacs) were previously shown to be implicated in Hey gene 
regulation (Iso et al., 2001b, Gould et al., 2009, Nakagawa et al., 2000, Takata and Ishikawa, 2003). 
Here, Hdac2 binding was assessed, because of its high expression in the used cells (rank 1 710 in ESC 
and 846 in CM). Other Hdacs were also expressed, but to a lower extent with Hdac1 being the second 
highest expressed Hdac after Hdac2 (rank 2 203 in ESC and in 3 265 in CM).  At the Cxcr4 locus, Hdac2 
binding correlates with Hey1 binding and is also increased in CM (figure 32D).  
The overexpression of Hey has no effect on histone acetylation in ESC, but there is a small reduction 
in CM (figure 32D), which might be a direct result of more Hey binding and Hdac recruitment. The 
increased Hey binding in CM might be caused by the higher baseline expression of Cxcr4 (figure 32C), 
as this might lead to more open chromatin, making the Cxcr4 promoter more accessible for binding of 
TF. However, genes, which are only repressed in CM, shown no mean increase in expression. 
5.2.9.3. Zfhx3 and Jag1 – Hey ES cell specific down-regulated genes 
Zfhx3 and Jag1 are both examples for genes, which are only down-regulated in ESC. Nevertheless both 
genes display very different Hey binding patterns. Zfhx3 shows a very similar Hey binding profile in ESC 
and CM (figure 33A), whereas Jag1 binding is nearly abolished in CM (figure 34A).  
Zfhx3 down-regulation was confirmed for ESC, but it was also possible to confirm this regulation in 
embryonic hearts of Hey1 overexpressing mice (figure 33B). However, Zfhx3 is not down-regulated in 
the differentiated CM. Base-line expression is reduced in CM and even stronger reduced in murine 
hearts (figure 33C). 
The ChIPseq results show no differences in Hey binding between ESC and CM (figure 33A). The extent 
of acetylation, however, is lower in ESC (max enrichment 4.4) compared to CM (max enrichment E14.5 
7.7/ adult 8.0). Here, acetylation correlates with down-regulation, in contrast to Hey binding. This is 
likely the case for most genes of this cluster. For Zfhx3 the acetylation sites seem to change, whereas 
they correlate with the Hey binding sites near the TSS and downstream of it in ESC, they are located 
near Hey binding sites upstream of the promoter that are also occupied by Gata4, Srf and Nkx2-5 in 
CM (figure 33A). This indicates that these factors might counteract the deacetylating effects of Hey via 
acetylation at specific sites.  
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Figure 33: Validation of the in ESC by Hey down-regulated gene Zfhx3 
A) Given are the ChIPSeq profiles for ESC and CM. The peak height is normalized to the 1000 highest peaks within 
each sample. H3K27ac is shown as heatmap for E14 ESC, mouse E14.5 embryonic and adult hearts. Values scale 
from 0 (white) to 5 (black) 
B) qRT-PCR results are derived from three independent biological samples (except CM-CM7/1 control – only one 
sample). The delta delta CT value to a non-induced or wild-type control is given. Error bars indicate the standard 
deviation. A student’s t-test was performed to identify significant differences (p-value ≤ 0.01 **; p-value ≤ 0.05 
*). 
C) delta delta CT value of the non-induced or wild-type controls compared to ES-Hey1. 
D) ChIP results from two replicates at four time points during CM differentiation for Hey1 and Hey2 over-
expressing cells. Flag-ChIP was performed after 48 h of low level doxycycline induction (50 ng/µl). ChIP against 
Hdac2 and H3ac was performed after 48 h of high level induction at which regulation was observed (1 µg/ml). 
Values below 1 % are not shown. 
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The binding site P1 shows a low level of Hey and Hdac2 binding independent of the differentiation 
status (figure 33D). Acetylation at this site is not affected by Hey overexpression, but is increased in 
CM, possibly as a result of Gata4, Srf, and/or Nkx2-5 binding. P2 shows no Hey or Hdac2 binding or 
acetylation and functions as a negative control. Biding sites P3 displays a high level of Hey and Hdac2 
binding during all stages of differentiation. Induction of Hey results in a reduced acetylation at this site 
in ESC. This Hey dependent reduction is gradually abolished starting from day 10 of differentiation. The 
site becomes strongly acetylated in CM independent of Hey overexpression, possibly again as a result 
of Gata4, Srf, and/or Nkx2-5 binding. P4 shows a reduction in Hey and Hdac2 binding during 
differentiation. Here, Hey dependent deacetylation was observed in ESC and at day 4 of differentiation, 
but not at later time points. 
Another example for a gene only down-regulated in ESC is Jag1 (figure 34B). However, here the 
ChIPseq data shows a dramatic difference in Hey binding between ESC and CM. Hey binding appears 
to be completely abolished in CM (figure 34A), although the gene remains comparably strong 
expressed (figure 34C). Therefore, the loss of Hey binding is not simply a result of the promoter 
becoming inaccessible due to condensed chromatin. Loss of Hey binding was confirmed by individual 
ChIP experiments. Hdac2 binding correlates with Hey binding and the reduction in acetylation 
(figure 34D). Like Zfhx3 the Jag1 promoter has several previously identified Gata4, Srf and/or Nkx2-5 
binding sites (figure 34A). 
Jag1 serves as an example for a gene, which behaves different from most genes within the group of 
genes only repressed in ESC. This points towards the existence of several different mechanisms for 
different genes, which may involve additional factors, that prevent Hey binding in CM e.g. at the Jag1 
promoter. 
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Figure 34: Validation of the in ESC by Hey down-regulated gene Jag1 
A) Given are the ChIPSeq profiles for ESC and CM. The peak height is normalized to the 1000 highest peaks within 
each sample. H3K27ac is shown as heatmap for E14 ESC, mouse E14.5 embryonic and adult hearts. Values scale 
from 0 (white) to 5 (black) 
B) qRT-PCR results are derived from three independent biological samples (except CM-CM7/1 control – only one 
sample). The delta delta CT value to a non-induced or wild-type control is given. Error bars indicate the standard 
deviation. A student’s t-test was performed to identify significant differences (p-value ≤ 0.01 **; p-value ≤ 0.05 
*). 
C) delta delta CT value of the non-induced or wild-type controls compared to ES-Hey1. 
D) ChIP results from two replicates at four time points during CM differentiation for Hey1 and Hey2 over-
expressing cells. Flag-ChIP was performed after 48 h of low level doxycycline induction (50 ng/µl). ChIP against 
Hdac2 and H3ac was performed after 48 h of high level induction at which regulation was observed (1 µg/ml). 
Values below 1 % are not shown. 
5.2.9.4. Bcl11a – a Hey down-regulated genes in ES cells and cardiomyocytes 
Bcl11a is an example for a gene, which is down-regulated by Hey in ESC and CM. However, this gene 
shows no down-regulation in the analyzed murine hearts (figure 35B), indicating that in vivo regulation 
might be different or limited to a subset of cells.  
For all time points during differentiation Hey binding is observed, as well as Hdac2 binding and histone 
deacetylation when Hey is overexpressed (figure 35D). The promoter has no previously identified 
Gata4, Srf or Nkx2-5 binding sites (figure 35A). 
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Figure 35: Validation of the Hey down-regulated gene Bcl11a 
A) Given are the ChIPSeq profiles for ESC and CM. The peak height is normalized to the 1000 highest peaks within 
each sample. H3K27ac is shown as heatmap for E14 ESC, mouse E14.5 embryonic and adult hearts. Values scale 
from 0 (white) to 5 (black) 
B) qRT-PCR results are derived from three independent biological samples (except CM-CM7/1 control – only one 
sample). The delta delta CT value to a non-induced or wild-type control is given. Error bars indicate the standard 
deviation. A student’s t-test was performed to identify significant differences (p-value ≤ 0.01 **; p-value ≤ 0.05 
*). 
C) delta delta CT value of the non-induced or wild-type controls compared to ES-Hey1. 
D) ChIP results from two replicates at four time points during CM differentiation for Hey1 and Hey2 over-
expressing cells. Flag-ChIP was performed after 48 h of low level doxycycline induction (50 ng/µl). ChIP against 
Hdac2 and H3ac was performed after 48 h of high level induction at which regulation was observed (1 µg/ml). 
Values below 1 % are not shown. 
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6. Discussion 
The strong phenotypes of Hey KO mice raise the question whether these are due to misregulation of 
Hey target genes that mediate the effects in various cell types. To gain insight into the regulatory 
potential of Hey proteins we employed an in vitro system with inducible expression of Hey proteins. 
Initially, HEK293 cells were used as a cellular model system as they are easy to manipulate and express 
endogenous Hey proteins suggesting that they can react appropriately to altered Hey protein levels. 
Additionally, ESC, which can be differentiated into CM, were used as these cells are more relevant 
especially for the observed cardiac phenotypes that result partially from loss of Hey1 and/or Hey2 
expression in atrial and ventricular CM. 
6.1. Hey proteins are redundant modulators of gene expression 
Previously, Hey proteins have been described mainly as repressors for a small number of individual 
target genes identified coincidentally by separate approaches (Fischer and Gessler, 2007). To identify 
a wider spectrum of regulated genes we used HEK293, ESC and CM with Hey overexpression. In all 
three cell types regulated genes overlap between Hey1 and Hey2, although with varying extend of 
regulation. For the more divergent family member HeyL more differences in target gene regulation 
were observed than between Hey1 and Hey2, but this might be partially due to methodical differences 
(microarray and RNAseq). However, it was possible to confirm divergent regulation by HeyL for some 
genes by qRT-PCR in HEK293 cells. Despite these differences, there is still a large overlap in regulation 
between HeyL and the other two Hey proteins. This redundancy is likely the result of dimerization 
between different Hey proteins (Iso et al., 2001, Leimeister et al., 2000, Fischer et al., 2007), when 
overexpressed tagged Hey1, Hey2 or HeyL proteins interact with endogenous Hey proteins.  
Surprisingly, the observed level of regulation of Hey proteins was rather limited in all analyzed cell 
types. Among the most down-regulated genes are Lefty1 and Lefty2 in ESC and Sema6d in CM (up to 3 
fold). In HEK293 cells the most down-regulated gene is the endogenous Hey1 (up to 5 fold), indicative 
of a negative feedback loop. Also for Hey2 and HeyL repression was seen, but to a lesser extent. The 
negative feedback on the Hey1 promoter was also confirmed by luciferase reporter assay. Similar 
negative feedback loops for Hes1 and Hes7 have previously been shown to be essential in 
somitogenesis and neural stem cell biology (Kageyama et al., 2010). During somite formation several 
components of the Notch signaling system are expressed in a cyclical fashion (Jouve et al., 2000, Bessho 
et al., 2001). This cycling is the result of expression and subsequent auto-repression. However, whether 
Hey proteins are also expressed in a cycling fashion is unclear. 
The generally modest expression changes suggest that Hey proteins modulate expression of already 
active target genes rather than completely switch expression states. This is also reflected in the 
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chromatin signature of corresponding promoters. There is a striking overlap in Hey binding sites with 
the presence of polymerase II and the active chromatin mark H3K4me3, arguing that Hey proteins 
modulate expression of active genes rather than switching expression on or off.  
However, low endogenous expression of Hey proteins may already affect target genes that can only 
be enhanced to a limited extent by further overexpression. Recently, it was shown that Hey2 
overexpression did not affect cardiac differentiation, whereas knockdown of Hey2 led to a modest 
effect on Anf expression (Hartman et al., 2014). However, the authors only analyzed few individual 
target genes, so the entire effect of Hey2 overexpression and knockdown remains unclear. 
6.2. Hey proteins bind redundantly to target sites 
We found a similar number of up- and down-regulated genes upon induction of Hey proteins, which 
was surprising as Hey proteins have previously been described as repressors. The observed regulation 
could be either due to direct or indirect effects on target promoters. To distinguish these, we 
conducted ChIP experiments to identify Hey binding sites within the genomes of the analyzed cell 
types. For these experiments we relied on a rather limited overexpression of Hey proteins in order to 
mimic a physiological situation. Nonetheless, a very large number of binding sites was identified for 
Hey1, Hey2 and even more so for HeyL. 
In differentiated cells such as the analyzed HEK293 and CM, the number of Hey1 and Hey2 binding 
sites is lower compared to undifferentiated ESC. ESC contain larger stretches of open chromatin, 
therefore more binding sites are accessible for TF. Differences between Hey1 and Hey2 are 
predominantly restricted to less enriched target sites. This translates to a Pearson’s correlation of 
r = 0.75 in HEK293 cells and r = 0.93/0.92 in ESC and CM, which is in the same range of values obtained 
for biological replicas (r = 0.83) in other studies (Ho et al., 2011). This shows that Hey1 and Hey2 largely 
bind the same targets independent of the analyzed cell type. 
For HeyL a much larger number of binding sites was identified in HEK293 cells. This finding was 
surprising considering that despite HeyL being more divergent than Hey1 and Hey2, DNA binding 
domains are largely conserved between all three proteins. However, the vast majority of Hey1 and 
Hey2 binding sites is also bound by HeyL in HEK293 cells.  
There is a huge discrepancy between the large number of ChIP peaks and the much smaller number of 
regulated genes for all three Hey proteins. This indicates that the vast majority of binding sites may 
not contribute to gene regulation, although endogenous Hey proteins may have already exhausted the 
regulatory potential of some of these sites. On the other hand, an overabundance of bound DNA 
sequences has also been observed for other TF e.g. Gata proteins and other HLH factors e.g. MyoD (He 
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et al., 2011, Cao et al., 2010). For functionally active binding sites additional modifications or 
concomitant binding of additional factors might be required.  
6.3. Hey proteins act as direct repressors on target promoters 
Binding sites shared between all three Hey proteins in HEK293 cells as well as Hey1 and Hey2 binding 
sites in ESC and CM are located near TSS. Considering these sites, the majority of Hey repressed genes 
are Hey targets, whereas up-regulation is mainly due to indirect effects as these genes do not have 
more Hey binding sites than other expressed but non-regulated genes. There is even a quantitative 
correlation between down-regulation and the amount of Hey binding in ESC and also in CM, when 
considering additional factors. Such a correlation was not found for up-regulated genes, which 
suggests that Hey expression leads to a repression of transcriptional activators for these genes.  
Direct repression of target promoters could also be verified in vitro by luciferase reporter assays. Up 
to 10-fold repression of target promoters by Hey1/2/L was previously demonstrated for e.g. Gata4/6 
promoters (Fischer et al., 2005). The here presented experiments provide additional proof for Hey 
function as direct repressors. The conserved bHLH and Orange domains can be turned into an activator 
of transcription when fused to the strong vp16 activation domain. Furthermore, mutation of three 
putative DNA binding arginine residues into lysine completely abolished promoter repression in 
luciferase assays, which clearly shows that direct binding of Hey proteins is required to affect target 
gene expression. This data clearly establishes Hey proteins as direct DNA binding transcriptional 
repressors. 
6.4. Hey proteins preferentially bind to E-box motifs 
Previously, a putative DNA binding motif tggCACGYGcca for Hey proteins has been identified by in vitro 
oligonucleotide selection (Fischer et al., 2002). However, the consensus E-box site CACGYG was either 
not present in target promoters analyzed previously, or deletion of related E-box sites did not alter 
expression of luciferase reporter constructs (Fischer and Gessler, 2007). Therefore, it was proposed 
that Hey functions indirectly, not via direct DNA binding. 
When applying a de novo motif discovery algorithm, it was possible to extract a corresponding E-box 
motif CACGYG from the most highly enriched shared Hey binding sites. The second most enriched motif 
GCGCGC does not resemble typical E-box properties. There is a positive correlation between motif 
occurrence rate of these motifs and Hey peak height, which indicates that the presence of an E-box 
binding motif aids in Hey binding.  
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Our in vitro data from EMSA assays shows that CACGTG is the preferred binding site of recombinant 
Hey1 protein. Related sequences are also bound but to lesser extent. Additionally, mutation of an 
E-box site within the Jag1 promoter abolished Hey regulation indicating that in vitro this site is required 
for Hey binding. However, even when considering only the most highly enriched binding sites identified 
in HEK293 cells, less than half of these contain CACGYG motifs. This suggests that Hey proteins may 
either use less stringent criteria for DNA binding in vivo or they might also bind in a manner that does 
not fully rely on sequence specificity as suggested for other HLH factors (Perna et al., 2011). Another 
explanation would be that certain sites are not directly bound by Hey proteins themselves but rather 
via TF that interact with Hey proteins via the HLH domain. 
6.5. Additional HeyL binding sites  
The most striking difference between all three Hey proteins in the here analyzed data sets are the 
many additional binding sites identified for HeyL. We considered that factors like the more efficient 
overexpression of HeyL in HEK293 cells and differences in methodology might be the cause. However, 
we could show at least for some of the additional bound sites that even much higher induction of Hey1 
or Hey2 does not lead to a comparable enrichment as observed for HeyL at lower induction. 
Additionally, using different Hey1-HeyL fusion constructs, we could show that binding to these 
additional sites is lost when the C-terminal domain of HeyL is replaced with the matching part of the 
Hey1 proteins. These findings argue against methodical reasons. 
The additional only by HeyL bound sites do not localize to TSS and are more scattered across the 
genome. HeyL binds these sites with a lower affinity compared to shared sites. The reason might be 
that sites are not enriched for an E-box motif, for which a positive correlation in peak height and motif 
concurrency was observed for the shared binding sites. Additional HeyL sites are also bound by CTCF 
and it was possible to recover GC rich motifs similar to the CTCF binding motif from these. Due to these 
differences in binding motif, we considered that HeyL does not directly bind to these sites, but rather 
interacts via its C-terminal domain with other TF that do not interact with Hey1 or Hey2. However, 
when we introduced the same mutation, which abolished target gene regulation and DNA binding for 
Hey1, not only binding to the shared sites, but also binding to the additional sites was lost. This 
demonstrates that they are also directly bound by HeyL. However, binding of additional sites might 
still depend on other factors that do not interact with Hey1 or Hey2. 
Although there are genes which are differently regulated by HeyL, it is unclear whether this is related 
to HeyL binding of additional sites. Due to the lower number of regulated genes and scattering of 
numerous additional HeyL sites, it is not obvious to assign these to certain genes. Nonetheless, when 
assigning them to the closest TSS there are no differences in peak height between genes that are 
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differently regulated by HeyL and genes with similar regulation by all three Hey proteins. Therefore, 
the functional role of these sites remains largely elusive. In order to follow these up, it would be 
interesting to study whether there are additional interaction partners, which HeyL does not share with 
Hey1 or Hey2, as up to now none are known. Additionally, the striking overlap to CTCF binding sites 
still remains to be elucidated. CTCF was shown to direct the 3D organization of the genome within the 
nucleus and to insulate enhancer elements (Phillips and Corces, 2009). However, Hey proteins have 
not been implicated in these processes so far.  
6.6. Hey factors regulate various developmental factors 
Overrepresented groups of GO terms for Hey regulated and bound genes include many other TF that 
are involved in various developmental processes including mesodermal and neuronal development in 
HEK293 cells, embryonic and cardiovascular development in ESC and CM and other developmental 
terms. This fits to the cardiovascular phenotypes observed in Hey KO mice and is also in line with the 
prototypic function of Enhancer of split genes in Drosophila that act on downstream neurogenic TF to 
control cell fate decision and differentiation (Fisher and Caudy, 1998). Additionally target genes are 
also involved in regulation of cell cycle and apoptosis. 
There are cell type specific differences. Regulation of neuronal genes in HEK293 cells might be related 
to the neuronal character of these cells and there is a shift away from repression of genes involved in 
cell migration in ESC to genes involved in cell cycle control in CM during differentiation. Repression of 
genes involved in cell migration (e.g. Nrp2) might be more relevant in other differentiation processes 
and other cell types, such as endocardial or endothelial cells, where misregulation of these genes might 
contribute to the observed EMT and vascular defects in Hey KO mice. In vessels Nrp2 expression is 
mostly confined to veins and lymphatic vessels, maybe due to repression by Hey2 that is present in 
arteries (Yuan et al., 2002).  
Genes repressed in CM are involved in cell cycle progression, differentiation and proliferation. They 
could potentially mediate anti-hypertrophic effects seen in Hey2 overexpressing mice and cause 
hypertrophy observed in mice with heterozygous Hey2 deletion upon pressure overload and even 
more so in Hey2 KO mice (Gessler et al., 2002, Donovan et al., 2002, Sakata et al., 2002, Kokubo et al., 
2004, Xiang et al., 2006, Liu et al., 2010). Transcripts regulated in CM are also enriched for genes 
involved in response to retinoic acid, which was previously shown to restrict the developmental 
potential of the heart field and to subsequently reduce cardiac proliferation. Reduced RA signaling 
leads to hypoplasia especially of the compact ventricular layer, where Hey2 is preferentially expressed 
and to a shift from ventricular to atrial differentiation, similar to Hey2 KO mice (Xin et al., 2007, 
Koibuchi and Chin, 2007, Lin et al., 2010, Zhang et al., 2011). 
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These data establishes Hey proteins near the top of a transcriptional hierarchy, with Notch and Bmp 
signaling acting directly upstream of Hey factors and many other TF downstream of them. The 
conducted experiments do not provide enough functional evidence to draw further conclusions about 
the regulation of specific genes and the functional implications during cardiovascular developmental. 
However, the provided data can be a vital source for further in vivo experiments. 
6.7. Hey target gene repression by Hdac recruitment and histone deacetylation 
In HEK293 cells we have found that Hey proteins bind primarily to active chromatin with H3K4me3 and 
in ESC and CM a similar observation was made. However, no differences in H3K4me3 were observed 
for differently regulated groups of target genes. Previously, it was reported that Hey proteins interact 
with the Sin3/N-CoR repressor complex, which recruits Hdac proteins, as well as with Sirt1 another 
histone deacetylase (Iso et al., 2001, Gould et al., 2009). Indeed, a reduction in H3K27ac was observed 
for Hey repressed genes. These findings suggest that Hey proteins might act on histone acetylation via 
recruitment of these deacetylases. However, as repression was also observed in vitro on luciferase 
promoter constructs, which are not embedded in chromatin, Hey proteins might also affect expression 
of target genes in other ways. 
In our analysis of individual Hey target promoters Hdac2 enrichment correlates largely with Hey 
enrichment. Additionally a reduction in histone H3 acetylation was observed. Previous studies could 
show that treatment with the Hdac inhibitor TSA can partially abolish Hey repression of target genes, 
as TSA does not inhibit Sirt1 another Hey interacting histone deacetylase (Takata and Ishikawa, 2003, 
Nakagawa et al., 2000). Furthermore, CM specific Hdac1 and Hdac2 KO mice exhibit strong cardiac 
phenotypes, indicating their relevance as important co-factors during cardiac development 
(Montgomery et al., 2007). These findings support the idea that Hey proteins indeed repress target 
promoters trough recruitment of histone deacetlyases. 
6.8. Cardiac activators can overwrite Hey down-regulation 
In CM, for a subset of genes binding of Hey proteins and recruitment of Hdac2 similar to ESC was 
observed, even though these genes were only repressed in ESC. However, when we analyzed histone 
acetylation, a reduction was only observed for genes that are actually down-regulated. Therefore, Hey 
binding and Hdac recruitment does not always have an impact on histone acetylation. Previous studies 
found that a few histone modifications can explain most of the observed gene expression, but data 
from many more TF can only explain a smaller fraction (McLeay et al., 2012). H3K27ac was shown to 
be among the most predictive histone modifications for gene expression (Karlic et al., 2010). This 
indicates that numerous TF act on a few histone modifications, leading to certain expression levels.  
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I identified cardiac activators, such as Gata proteins, Nkx2-5 and Srf as other important factors in the 
regulation of Hey target genes. These three factors co-localize on cardiac enhancers (He et al., 2011). 
They were shown to recruit histone acetylases such as p300 and activate the cardiac expression 
program. It appears that for a set of Hey bound genes, the acetylating effects of these factors 
overpower Hey mediated deacetylation. This leads to hyperacetylation of target promoters and 
prevents Hey mediated repression. However, cardiac activators do not interfere with Hey binding as 
recruitment to target promoters is in most cases unchanged. 
A recent investigation on target gene regulation during AVC specification also implicated combinatory 
effects between Hey and Gata factors on target genes (Stefanovic S., in press). Here the authors could 
show that Hey proteins expressed in atrial and ventricular CM prevent Gata dependent gene activation 
outside the AVC, thereby defining the borders of that region. On one hand, it appears that activation 
of some genes by Gata4 is overwritten by Hey in atrial and ventricular CM. On the other hand, high 
binding of cardiac activators including Gata4 is able to overpower repression by Hey proteins for other 
genes in CM. These combined findings indicate that whether a gene is down-regulated depends on the 
ratio of Hey binding and binding of these cardiac activators. 
Previous studies found also that Hey proteins directly interact with Gata4 and Srf. In such complexes 
Hey proteins act as co-repressors and abolish target gene activation (Elagib et al., 2004, Kathiriya et 
al., 2004, Fischer et al., 2005, Doi et al., 2005) indicating even more complex regulatory mechanism. 
 
 
 
 
 
 
 
6.9. Model for Hey target gene regulation  
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Figure 36: Model of Hey target gene regulation in ESC and CM 
Hey proteins directly repress target genes via binding close to TSS, preferentially to E-box motfis. They recruit 
histone deacetylases (Hdac), which deacetylate histones, leading to chromatin condensation and reduced 
expression of target genes. In CM this can be counteracted by binding of cardiac activators (Srf, Gata4, Nkx2-5), 
which recruit histone acetylases (p300). 
Here we could show, that Hey repression of target genes correlates with Hdac recruitment and histone 
deacetylation, which likely results in chromatin condensation. This renders target promoters less 
accessible and results in a down-regulation of target genes. However, histone deacetylation can be 
overwritten for a subset of genes in CM by cardiac activators (Srf, Gata4, Nkx2-5). This is achieved by 
counteracting Hey mediated histone deacetylation by recruitment of histone acetylases such as p300. 
This mechanism leads to cell type and gene specific regulation of Hey target genes. 
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8. Supplement 
8.1. Supplementary Information 
 
Figure 37: Additional HeyL binding sites at HIVEP and PXT1 loci are no artefact 
(A) For Hey1 and HeyL ChIP experiments after induction with different doxycycline concentration were carried 
out. Shown is the enrichment for the two binding peaks (p1 and p2) for the HIVEP and PXT1 loci, with the shared 
peaks p1 in red. 
(B) HEK293T cells were transiently transfected with pCS2p-Flag/HA-Hey1/L constructs. Enrichment was 
determined for the two binding peaks (p1 and p2). The shared peak p1 is indicated by a red box. 
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Figure 38: Heterodimer binding at HIVEP and PXT1 loci 
HEK293T cells were transiently co-transfected with pCS2p-HA-HeyL and pCS2p-Flag-Hey1, -Hey2 or -HeyL 
constructs. As control cells were either only transfected with pCS2p-Flag-Hey1 or –HeyL or empty pCS2p-Flag 
(mock). First a Flag-ChIP was carried out for all samples, after that half of the eluted chromatin was used for the 
HA-ReChIP.  The enrichment was determined for the Flag-ChIP and the HA-ReChIP samples for the two binding 
peaks (p1 – p2) at the HIVEP and PXT1 loci. The shared peak p1 is indicated by a red box. 
 
Figure 39: Binding of chimeric Hey1-HeyL proteins at HIVEP and PXT1 loci 
HEK293T cells were transfected with pCS2p-Flag-Hey constructs expressing either Hey1, HeyL or two chimeric 
proteins containing either the c-terminal part of Hey1 and the n-terminal part of HeyL (HeyL-1) or vice versa 
(Hey1-L). The enrichment was determined the two binding peaks (p1 – p2) at the HIVEP and PXT1 loci. The shared 
peak p1 is indicated by a red box. 
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Figure 40: Binding of Hey1-L-RK3 nonbinding mutant at HIVEP and PXT1 locus 
(A) HEK293T cells were transfected with pCS2p-Flag-Hey constructs expressing either Hey1, the chimeric Hey1-L 
protein containing the c-terminal part of Hey1 and the n-terminal part of HeyL and the Hey1-L-RK3 mutant, with 
3 point mutations in the binding sites, which abolishes DNA binding. The enrichment was determined for the two 
binding peaks (p1 – p2) at the HIVEP and PXT1 loci. The shared peak p1 is indicated by a red box. 
 
Figure 41: Average ChIPSeq peak height in Hey regulated genes in HEK293 cells 
(A) For the two groups of differently and similarly regulated genes the average peak height of peaks located in 
the promoter region (-1 kb to +1 kb) was determined. Peaks were normalized according to the average peak 
height of the 1000 highest peaks, within each sample. Stars indicate significant and highly significant differences 
according to a student’s t-test. 
(B) The same was done for all distal peaks (more than 1 kb away from the closest TSS). 
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Figure 42: Marker expression during differentiation with prologned Hey1 or Hey2 overexpression 
RNA was isolated from non- and continuously induced (1 µg/ml dox from day -2 until cells were harvested) ES-
Hey1 and ES-Hey2 cells before differentiation (ESC), at days 3, 5, 7, 9, 12, 14, 15 of differentiation and 
differentiated CM from three independent differentiations. Lines show the mean change compared to non-
induced ESC, error bars indicate the standard deviation. 
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Table 8: ChIPseq total reads for HEK293 cells 
  Hey1 +dox Hey2 -dox Hey2 +dox HeyL -dox HeyL +dox 
total reads 13073816 13525913 14040194 16142238 15142197 
mapped reads 12250465 9047086 12386941 15137928 13839026 
mapped reads % 93.7 66.8 88.2 93.8 91.4 
 
Table 9: RNAseq total reads for HEK293-ptol2-mHeyL 
  HeyL -dox HeyL +dox 
total reads 4645098 4471381 
mapped reads 4217498 3831625 
mapped reads % 90.8 85.7 
 
Table 10: ChIPseq total reads for ESC 
  Hey1 -dox Hey1 +dox Hey2 -dox Hey2 +dox 
total reads 13212856 19776762 13318035 17967960 
mapped reads 11773144 17849853 11732914 16456164 
mapped reads % 89.1 90.3 88.1 91.6 
 
Table 11: ChIPseq total reads for CM 
  Hey1 -dox Hey1 +dox Hey2 -dox Hey2 +dox 
total reads 18200688 18360337 15328934 16704134 
mapped reads 14324108 15684074 7979212 7119052 
mapped reads % 78.7 85.4 52.1 42.6 
 
Table 12: RNAseq total reads for CM 
  Hey1 -dox Hey1 +dox Hey2 -dox Hey2 +dox 
total reads 8347129 8547469 12738990 22848834 
mapped reads 7381914 7549578 11526903 20751945 
mapped reads % 88.4 88.3 90.5 90.8 
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Table 13: EMSA oligonucleotides 
ChIP-Ebox-bio1 [BTN]GTGTTATGGCACGTGCCATACTG  
ChIP-Ebox-bio2 [BTN]GCAGTATGGCACGTGCCATAACA 
ChIP-Ebox1 GTGTTATGGCACGTGCCATACTG  
ChIP-Ebox2 GCAGTATGGCACGTGCCATAACA 
ChIP-Ebox1-CGCGCG GTGTTATGGCGCGCGCCATACTG 
ChIP-Ebox2-CGCGCG GCAGTATGGCGCGCGCCATAACA 
ChIP-Ebox1-CACGCG GTGTTATGGCACGCGCCATACTG 
ChIP-Ebox2-CACGCG GCAGTATGGCGCGTGCCATAACA 
 
Table 14: Oligonucleotides for cloning 
Hey1ArgLysint_5 GATTTTGGCCAAAAAAAGACGGAAAGGAATAATTGAGAAG 
Hey1ArgLysint_3 GATCCGGTCTTTTCGGCGCTTCTCAATTATTCC 
mHeyL_ArgLys_int_rev TTTGCGCCGTTTCTCTATGATCCCTTTGCGCTTCTTTTTCGCCAAAACCTG 
mHeyL_ArgLys_int_for AAAAAGAAGCGCAAAGGGATCATAGAGAAACGGCGCAAAGACCGCAT 
Hey1_PauI_rev GCGGCGCGCCAAAACCTGGGACGATG 
HeyL_PauI_for GCGGCGCGCAAGAAGCGCAGAGGGA 
HeyL_AlfII_rev GCGCTTAAGGTGGGAGAGGAGGCGA 
Hey1_AlfII_for GCGCTTAAGAACTACGCATCCCAGC 
 
Table 15: Human oligonucleotides for qRT-PCR 
hDhrs2-real-for ACCAGTGAGCAGATCTGGGA 
hDhrs2-real-rev TCCATGTAGGGCAGCAACTG 
hFGF2-real-f CCTGGCTATGAAGGAAGATGG 
hFGF2-real-r TCTGCCCAGGTCCTGTTTT 
hHey1 total (Clikseq5) ACCCCAAACTCCGATAGTCC 
hHey1 total (huclik-3) TGAGCTGAGAAGGCTGGTAC 
hHey1-real3-ex2  (endogenous) GGGGACATGGAACCTAGAGC 
hHey1-real5-ex1 (endogenous) CCAGCATGAAGCGAGCTCAC 
hHey2-realex1-f (endogenous) GGAAAGTTGTGACGGTCGAG 
hHey2-realex3-r (endogenous) CCGACGCCTTTTCTCTATAATCC 
hHeyL-realex1-f (endogenous) CCGACTGGGAGCCTTAGC 
hHeyL-realex2-r (endogenous) GTTTCTTCCTGGCTTGCATCT 
hHPRT_3’real_neu2   GTCAAGGGCATATCCTACAACAA 
hHPRT_5’real_neu2   AAGATGGTCAAGGTCGCAAG 
hMMP2-real1 GAATGCCATCCCCGATAAC 
hMMP2-real2 TTGGTTCTCCAGCTTCAGGT 
hPlxnA2-real3' AATCACGTTCACCCAGAAGC 
hPlxnA2-real5' TCCTAGATGAGCAGGCAGACA 
hScara5-real-for CTGTCCTGGGGCTCTACCTG 
hScara5-real-rev CCCGGAAGCTCTCATTCAGC 
hSlc16a7-real-for GCAATGGTTCACAAGGAAACT 
hSlc16a7-real-rev TCTGCTCCTCTAGTGGAAATTCA 
hSpsb4-real-for ACCAGTGAGCAGATCTGGGA 
hSpsb4-real-rev TCCATGTAGGGCAGCAACTG 
hSrgap1-real-for CACTTGAAGCCACCAATGCC 
hSrgap1-real-rev AGGGCTCTGTTCAGACTTGC 
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Table 16: Human oligonucleotides for ChIP 
hEYA4-p1-for CTCACGAGCCCGCAGTAG 
hEYA4-p1-rev CTTCACGTGGACAGGATGG 
hEYA4-p2-for CACAGGCCTTTCTTCCTCTG 
hEYA4-p2-rev ATGGCAATCTGCCCATTAAG 
hEYA4-p3-for CAGGTGGAATGCACACACTC 
hEYA4-p3-rev TTTCAGGTTTGGACAGCACA 
hEYA4-p4-for CATGCTAGAGCCTGGGAAAA 
hEYA4-p4-rev ATTTTGTCTCCCGTTCGATG 
hHivep2_p1_for GGTGCACGTCGCTCATTAGT 
hHivep2_p1_rev GCGGATCTATGCAGATGAGG 
hHivep2_p2_for CACCACACATCAAAGCCAGA 
hHivep2_p2_rev CCACGTCCCAGTTTGCTATT 
hPxt1_p1_for GCAGAGTGGACTGGAGGAAA 
hPxt1_p1_rev GCGCTTCACGTTAAGAGTCC 
hPxt1_p2_for CAGGTTAGGCGATAGAGGTCA 
hPxt1_p2_rev AACCCGGCCTCCCTAACT 
 
Table 17: Mouse oligonucleotides for qRT-PCR 
mAgtrl1-real3' ATACAGCCACCTGCTGGTTC 
mAgtrl2-real5' CCCTTCCCCTCAAACCTTCC 
mApln-real3' GGTAGCGCATGCTTCCTTCT 
mApln-real5' ATGAATCTGAGGCTCTGCGT 
mBcl11a-real3' GCTTCCATCCGAAAACTGCC 
mBcl11a-real5' GCACGCCCCATATTAGTGGT 
mCalca-real3' AGTGTTGCAGGATCTCTTCTGA 
mCalca-real5' CACTGGTGCAGGACTATATGC 
mCxcr4-real3' AGGTGCAGGTAGCAGTGACC     
mCxcr4-real5' ACTCACACTGATCGGTTCCA     
mDub1-real3' CAGCTAGAGGTGGTGTGTGTGT 
mDub1-real5' CTCTTTCCTTCCCAGAAGCAG 
mEnpp2-real3' TCGAGGGCGAGAGAAGTTTA     
mEnpp2-real5' AAAAGAATGTCCCGGCTCTC     
mHey1 endogenous (Clik-race) ATTCTCGTCCGCGCTCTCCTTTTCC 
mHey1 endogenous (mHey1-5’UTR) CTGCAGTTAACTCCTCCTTGC  
mHey1 total (clikseq5) CTGGCCAAAACCTGGGAC 
mHey1 total (huclik3) TGAGCTGAGAAGGCTGGTAC 
mHey2 endogenous  (mHey2-real-e2rev) GTCGGTGAATTGGACCTCAT 
mHey2 endogenous (mHey2-real-e1for) AGTAGCTGCTCCTCCTTCGTC 
mHey2 total (mHey2-real-e3for) TGAGAAGACTAGTGCCAACAGC 
mHey2 total (mHey2-real-e5rev) TGGGCATCAAAGTAGCCTTTA 
mHeyL-real-ex2/3 GAAGCGCAGAGGGATCATAG 
mHeyL-real-ex4rev GGCATGGAGCATCTTCAAGT 
mHPRT-real-ex8 TGTTGTTGGATATGCCCTTG 
mHPRT-real-ex9 ACTGGCAACATCAACAGGACT 
mId2-real3' CTCCTGGTGAAATGGCTGAT 
mId2-real5' GGACATCAGCATCCTGTCCT 
mJag1-real3’ CTCAGCAGAGGAACCAGGAA 
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mJag1-real5’ CTCGTTAGTAAACGGGATGGAA 
mKcnip1-real3' CTGTCTGGGTGGTGTCGAAG 
mKcnip1-real5' CGCTCAGTTTTTCCCTCACG 
mKrt7-real3' CCATTCCGTCTCCAGACAAC 
mKrt7-real5' ATCGCAGAGGCTGAGGAAC 
mLefty1-real3’ GACACCAGGAACCTGCCTGCCACCTCTC 
mLefty1-real5’ GGCTCTGCTGGGCACTCTGGGCACT 
mLefty2-real3' CGAGGCCCCAGAAATGGCCACCCGA 
mLefty2-real5' ACGCCGGACGGCAAGGGGCAG 
mMHC-alpha-3' CGCGAATTCGCAGAGTCGAACGTTTATGTTT 
mMHC-alpha-5' CGCGGATCCACGACGAGGAATAACC 
mMHC-beta-3' CGCGAATTCCTTTATTCTGCTTCCACCTA 
mMHC-beta-5' CGCGGATCCTGAATGAGGAGTAGATCTTG 
mMixl1_real3' TGCTACCCGAGTCCAGGAT      
mMixl1_real5' CCTTGAGGATAAGGGCTGAA     
mMLC-1A-3' CGCGAATTCAAGCTGGGGCTCTTTATTTC 
mMLC-1A-5' CGCGGATCCGGGTAAAGCACGTTTCTC 
mMLC-1V-3' CGCGAATTCTAAGGCCACAGGGTGGATAC 
mMLC-1V-5' CGCGGATCCGAGCTGAGCCTCTCAGGAAG 
mMLC-2a-3' CGCGAATTCAGGCACAGAGTTTATTGAGG 
mMLC-2a-5' CGCGGATCCGAGGAAGCCATCCTGAGT 
mMLC-2v-3' CGCGAATTCCTGTTTATTTGCGCACAGC 
mMLC-2v-5' CGCGGATCCTTAAAGGGGCTGATCCTGAA 
mNanog-real3' GAGGAAGGGCGAGGAGAG 
mNanog-real5' TTGCCTAGTTCTGAGGAAGCA 
mNr2f2-real3' CAGGTACGAGTGGCAGTTGA 
mNr2f2-real5' AGTACTGCCGCCTCAAAAAG 
mOct4-real3' GAAGCGACAGATGGTGGTCT 
mOct4-real5' CCGTGAAGTTGGAGAAGGTG 
mPlcb4-real3' CATCGCCAGTCTCTTTCTTTCT 
mPlcb4-real5' GAAAATAGCAAGGCCATCAGTC 
mRassf8_real3' GATGGGGTTTTCATGCGGTG 
mRassf8_real5' ACGGAAGTCACAACTTGCCA 
mSema3e-real3' GAGGAAGAGCAAGCCCAAG 
mSema3e-real5' CGTTGGACAGGACTGAAGAGA 
mSema6D-real3' GACCACCTTTCTGTCCTCCTC 
mSema6D-real5' CTGAAGCTGGCGTGGTACTT 
mSgcg-real3' GGGGCATCCATGCTTAGACT 
mSgcg-real5' CGTAACAGGGCCAGAAGGAG 
mSox2_fwd_mus AAGGGTTCTTGCTGGGTTTT 
mSox2_rev_mus AGACCACGAAAACGGTCTTG 
mTcf3-real3' GTAGCTGTCACCTGAGCTGG 
mTcf3-real5' GTGGCCTGGCAGATACTCAG 
mTgm1-real3' GTGCACTTGGGAAAGCTGTG 
mTgm1-real5' ACAGAGACCCAAGGTCCTCA 
mZfhx3-real3' ATTGCACCCAGTACGGATCG 
mZfhx3-real5' CTGGGGTGGGTAAGTTCGG 
mZic2-real3' GCGCCGGTCACAGCCCTCGAACTCA 
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mZic2-real5' GCACGTCGGCGGCCCGGAACA 
 
Table 18: Mouse oligonucleotides for ChIP 
mBcl11a-p1-for ACTTTTTCCACCCCCTTCC 
mBcl11a-p1-rev TTGTTGTGATTTCGGGCTTC 
mCxcr4-p1-for GGAGAAAAGGGTGGGGTCAG 
mCxcr4-p1-rev GGAGAAAAGGGTGGGGTCAG 
mJag1-p1-for CCTCTCGGCTTTCTTTCCTT 
mJag1-p1-rev CACGCGTCATTGTGTTACCT 
mZfhx3-p1-for GCTGCACCCTGGACACTAG 
mZfhx3-p1-rev GTCCTCCGATCCGTTGTCTG 
mZfhx3-p2-for TCTGGCTCGGAGAATGGGTA 
mZfhx3-p2-rev CTTTCCTTCCCTGGCCTCAG 
mZfhx3-p3-for ACTGGAATCTCCCGTTGTCG 
mZfhx3-p3-rev CACAAAGCCTCCGTACACCT 
mZfhx3-p4-for CTAAGTGAGCAGCCCACTCC 
mZfhx3-p4-rev ACAAGCCAGGACAAGTCAGG 
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